PMID- 23541952
OWN - NLM
STAT- MEDLINE
DA  - 20130419
DCOM- 20130919
LR  - 20150325
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 4
DP  - 2013 Apr 15
TI  - Control of autophagic cell death by caspase-10 in multiple myeloma.
PG  - 435-49
LID - 10.1016/j.ccr.2013.02.017 [doi]
LID - S1535-6108(13)00073-1 [pii]
AB  - We performed a loss-of-function RNA interference screen to define therapeutic
      targets in multiple myeloma, a genetically diverse plasma cell malignancy.
      Unexpectedly, we discovered that all myeloma lines require caspase-10 for
      survival irrespective of their genetic abnormalities. The transcription factor
      IRF4 induces both caspase-10 and its associated protein cFLIPL in myeloma,
      generating a protease that does not induce apoptosis but rather blocks an
      autophagy-dependent cell death pathway. Caspase-10 inhibits autophagy by cleaving
      the BCL2-interacting protein BCLAF1, itself a strong inducer of autophagy that
      acts by displacing beclin-1 from BCL2. While myeloma cells require a basal level 
      of autophagy for survival, caspase-10 tempers this response to avoid cell death. 
      Drugs that disrupt this vital balance may have therapeutic potential in myeloma.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Lamy, Laurence
AU  - Lamy L
AD  - Metabolism Branch, Center for Cancer Research, National Cancer Institute,
      National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA.
FAU - Ngo, Vu N
AU  - Ngo VN
FAU - Emre, N C Tolga
AU  - Emre NC
FAU - Shaffer, Arthur L 3rd
AU  - Shaffer AL 3rd
FAU - Yang, Yandan
AU  - Yang Y
FAU - Tian, Erming
AU  - Tian E
FAU - Nair, Vinod
AU  - Nair V
FAU - Kruhlak, Michael J
AU  - Kruhlak MJ
FAU - Zingone, Adriana
AU  - Zingone A
FAU - Landgren, Ola
AU  - Landgren O
FAU - Staudt, Louis M
AU  - Staudt LM
LA  - eng
SI  - GEO/GSE43878
GR  - P01 CA055819/CA/NCI NIH HHS/United States
GR  - ZIA BC011010-06/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20130328
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Caspase Inhibitors)
RN  - EC 3.4.22.- (Caspase 10)
SB  - IM
CIN - Cancer Cell. 2013 Apr 15;23(4):425-6. PMID: 23597558
MH  - Apoptosis/drug effects/physiology
MH  - Autophagy/drug effects/*physiology
MH  - Caspase 10/*genetics/*metabolism
MH  - Caspase Inhibitors/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects/physiology
MH  - Gene Knockdown Techniques
MH  - Humans
MH  - Multiple Myeloma/drug therapy/*enzymology/genetics/*pathology
MH  - RNA Interference
PMC - PMC4059832
MID - NIHMS449657
OID - NLM: NIHMS449657
OID - NLM: PMC4059832
EDAT- 2013/04/02 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/04/02 06:00
PHST- 2012/03/28 [received]
PHST- 2013/01/30 [revised]
PHST- 2013/02/20 [accepted]
PHST- 2013/03/28 [aheadofprint]
AID - S1535-6108(13)00073-1 [pii]
AID - 10.1016/j.ccr.2013.02.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Apr 15;23(4):435-49. doi: 10.1016/j.ccr.2013.02.017. Epub 2013 
      Mar 28.

PMID- 23523103
OWN - NLM
STAT- MEDLINE
DA  - 20130419
DCOM- 20130919
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 4
DP  - 2013 Apr 15
TI  - Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is
      decreased in pancreatic cancer.
PG  - 464-76
LID - 10.1016/j.ccr.2013.02.005 [doi]
LID - S1535-6108(13)00068-8 [pii]
AB  - Tumor cells commonly have increased glucose uptake and lactate accumulation.
      Lactate is produced from pyruvate by lactate dehydrogenase A (LDH-A), which is
      frequently overexpressed in tumor cells and is important for cell growth.
      Elevated transcription by c-Myc or HIF1alpha may contribute to increased LDH-A in
      some cancer types. Here, we show that LDH-A is acetylated at lysine 5 (K5) and
      that this acetylation inhibits LDH-A activity. Furthermore, the K5-acetylated
      LDH-A is recognized by the HSC70 chaperone and delivered to lysosomes for
      degradation. Replacement of endogenous LDH-A with an acetylation mimetic mutant
      decreases cell proliferation and migration. Importantly, K5 acetylation of LDH-A 
      is reduced in human pancreatic cancers. Our study reveals a mechanism of LDH-A
      upregulation in pancreatic cancers.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Zhao, Di
AU  - Zhao D
AD  - Ministry of Education Key Laboratory of Molecular Medicine, Shanghai Medical
      College and State Key Laboratory of Genetic Engineering, School of Life Sciences,
      Fudan University, Shanghai 200032, China.
FAU - Zou, Shao-Wu
AU  - Zou SW
FAU - Liu, Ying
AU  - Liu Y
FAU - Zhou, Xin
AU  - Zhou X
FAU - Mo, Yan
AU  - Mo Y
FAU - Wang, Ping
AU  - Wang P
FAU - Xu, Yan-Hui
AU  - Xu YH
FAU - Dong, Bo
AU  - Dong B
FAU - Xiong, Yue
AU  - Xiong Y
FAU - Lei, Qun-Ying
AU  - Lei QY
FAU - Guan, Kun-Liang
AU  - Guan KL
LA  - eng
GR  - R01 CA108941/CA/NCI NIH HHS/United States
GR  - R01 CA132809/CA/NCI NIH HHS/United States
GR  - R01 CA163834/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130321
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Isoenzymes)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
RN  - EC 1.1.1.27.- (lactate dehydrogenase 5)
RN  - EC 3.5.1.- (SIRT2 protein, human)
RN  - EC 3.5.1.- (Sirtuin 2)
RN  - K3Z4F929H6 (Lysine)
SB  - IM
MH  - Acetylation
MH  - Animals
MH  - Autophagy/physiology
MH  - Cell Growth Processes/physiology
MH  - Cell Movement/physiology
MH  - Down-Regulation
MH  - Gene Knockdown Techniques
MH  - HeLa Cells
MH  - Humans
MH  - Isoenzymes/antagonists & inhibitors/genetics/metabolism
MH  - L-Lactate Dehydrogenase/antagonists & inhibitors/genetics/*metabolism
MH  - Lysine/*metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Pancreatic Neoplasms/enzymology/*metabolism/pathology
MH  - Sirtuin 2/genetics/metabolism
MH  - Transfection
MH  - Transplantation, Heterologous
PMC - PMC3885615
MID - NIHMS445885
OID - NLM: NIHMS445885
OID - NLM: PMC3885615
EDAT- 2013/03/26 06:00
MHDA- 2013/09/21 06:00
CRDT- 2013/03/26 06:00
PHST- 2012/05/22 [received]
PHST- 2012/12/07 [revised]
PHST- 2013/02/06 [accepted]
PHST- 2013/03/21 [aheadofprint]
AID - S1535-6108(13)00068-8 [pii]
AID - 10.1016/j.ccr.2013.02.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Apr 15;23(4):464-76. doi: 10.1016/j.ccr.2013.02.005. Epub 2013 
      Mar 21.

PMID- 23518352
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - SnapShot: pancreatic cancer.
PG  - 424-424.e1
LID - 10.1016/j.ccr.2013.03.008 [doi]
LID - S1535-6108(13)00086-X [pii]
FAU - Han, Haiyong
AU  - Han H
AD  - Translational Genomics Research Institute, Phoenix, AZ 85004, USA.
FAU - Von Hoff, Daniel D
AU  - Von Hoff DD
LA  - eng
GR  - U01 CA128454/CA/NCI NIH HHS/United States
GR  - U01 CA128454/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
MH  - *Carcinoma, Pancreatic Ductal/epidemiology/metabolism/pathology/therapy
MH  - Humans
MH  - Incidence
MH  - *Pancreatic Neoplasms/epidemiology/genetics/pathology/therapy
MH  - Risk Factors
MH  - Survival Rate
PMC - PMC3638898
MID - NIHMS456880
OID - NLM: NIHMS456880
OID - NLM: PMC3638898
EDAT- 2013/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/23 06:00
AID - S1535-6108(13)00086-X [pii]
AID - 10.1016/j.ccr.2013.03.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):424-424.e1. doi: 10.1016/j.ccr.2013.03.008.

PMID- 23518351
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20131121
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - The histone demethylase PHF8 governs retinoic acid response in acute
      promyelocytic leukemia.
PG  - 376-89
LID - 10.1016/j.ccr.2013.02.014 [doi]
LID - S1535-6108(13)00070-6 [pii]
AB  - While all-trans retinoic acid (ATRA) treatment in acute promyelocytic leukemia
      (APL) has been the paradigm of targeted therapy for oncogenic transcription
      factors, the underlying mechanisms remain largely unknown, and a significant
      number of patients still relapse and become ATRA resistant. We identified the
      histone demethylase PHF8 as a coactivator that is specifically recruited by
      RARalpha fusions to activate expression of their downstream targets upon ATRA
      treatment. Forced expression of PHF8 resensitizes ATRA-resistant APL cells,
      whereas its downregulation confers resistance. ATRA sensitivity depends on the
      enzymatic activity and phosphorylation status of PHF8, which can be
      pharmacologically manipulated to resurrect ATRA sensitivity to resistant cells.
      These findings provide important molecular insights into ATRA response and a
      promising avenue for overcoming ATRA resistance.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Arteaga, Maria Francisca
AU  - Arteaga MF
AD  - Leukaemia and Stem Cell Biology Group, Department of Haematological Medicine,
      King's College London, Denmark Hill, London SE5 9NU, UK.
FAU - Mikesch, Jan-Henrik
AU  - Mikesch JH
FAU - Qiu, Jihui
AU  - Qiu J
FAU - Christensen, Jesper
AU  - Christensen J
FAU - Helin, Kristian
AU  - Helin K
FAU - Kogan, Scott C
AU  - Kogan SC
FAU - Dong, Shuo
AU  - Dong S
FAU - So, Chi Wai Eric
AU  - So CW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Transcription Factors)
RN  - 0 (retinoic acid receptor alpha)
RN  - 1W21G5Q4N2 (Okadaic Acid)
RN  - 5688UTC01R (Tretinoin)
RN  - EC 1.14.11.- (Histone Demethylases)
RN  - EC 1.14.11.27 (PHF8 protein, mouse)
SB  - IM
MH  - Animals
MH  - Drug Resistance, Neoplasm
MH  - Histone Demethylases/genetics/*metabolism
MH  - Histones
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*drug therapy/*metabolism
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Neoplasm Proteins/metabolism
MH  - Okadaic Acid/pharmacology
MH  - Oncogene Proteins, Fusion/metabolism
MH  - Phosphorylation
MH  - RNA Interference
MH  - RNA, Small Interfering
MH  - Receptors, Retinoic Acid/genetics/*metabolism
MH  - Signal Transduction
MH  - Transcription Factors/genetics/*metabolism
MH  - Transcription, Genetic
MH  - Tretinoin/*pharmacology
MH  - Tumor Cells, Cultured
EDAT- 2013/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/23 06:00
PHST- 2012/05/14 [received]
PHST- 2012/11/26 [revised]
PHST- 2013/02/15 [accepted]
AID - S1535-6108(13)00070-6 [pii]
AID - 10.1016/j.ccr.2013.02.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):376-89. doi: 10.1016/j.ccr.2013.02.014.

PMID- 23518350
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia
      initiation and progression.
PG  - 362-75
LID - 10.1016/j.ccr.2013.01.025 [doi]
LID - S1535-6108(13)00044-5 [pii]
AB  - The molecular mechanisms regulating leukemia-initiating cell (LIC) function are
      of important clinical significance. We use chronic myelogenous leukemia (CML) as 
      a model of LIC-dependent malignancy and identify the interaction between the
      ubiquitin ligase Fbw7 and its substrate c-Myc as a regulator of LIC homeostasis. 
      Deletion of Fbw7 leads to c-Myc overexpression, p53-dependent LIC-specific
      apoptosis, and the eventual inhibition of tumor progression. A decrease of either
      c-Myc protein levels or attenuation of the p53 response rescues LIC activity and 
      disease progression. Further experiments showed that Fbw7 expression is required 
      for survival and maintenance of human CML LIC. These studies identify a ubiquitin
      ligase:substrate pair regulating LIC activity, suggesting that targeting of the
      Fbw7:c-Myc axis is an attractive therapy target in refractory CML.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Reavie, Linsey
AU  - Reavie L
AD  - Howard Hughes Medical Institute and Department of Pathology, New York University 
      School of Medicine, New York, NY 10016, USA.
FAU - Buckley, Shannon M
AU  - Buckley SM
FAU - Loizou, Evangelia
AU  - Loizou E
FAU - Takeishi, Shoichiro
AU  - Takeishi S
FAU - Aranda-Orgilles, Beatriz
AU  - Aranda-Orgilles B
FAU - Ndiaye-Lobry, Delphine
AU  - Ndiaye-Lobry D
FAU - Abdel-Wahab, Omar
AU  - Abdel-Wahab O
FAU - Ibrahim, Sherif
AU  - Ibrahim S
FAU - Nakayama, Keiichi I
AU  - Nakayama KI
FAU - Aifantis, Iannis
AU  - Aifantis I
LA  - eng
GR  - 1R01CA173636/CA/NCI NIH HHS/United States
GR  - 1T32CA160002-01/CA/NCI NIH HHS/United States
GR  - 5T32HL007151-33/HL/NHLBI NIH HHS/United States
GR  - R01 CA105129/CA/NCI NIH HHS/United States
GR  - R01 CA133379/CA/NCI NIH HHS/United States
GR  - R01 CA149655/CA/NCI NIH HHS/United States
GR  - R01CA105129/CA/NCI NIH HHS/United States
GR  - R01CA133379/CA/NCI NIH HHS/United States
GR  - R01CA149655/CA/NCI NIH HHS/United States
GR  - R01GM088847/GM/NIGMS NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (F-Box Proteins)
RN  - 0 (Fbxw7 protein, mouse)
RN  - 0 (Myc protein, mouse)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 6.3.2.19 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Disease Progression
MH  - F-Box Proteins/genetics/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Hematopoietic Stem Cells
MH  - Humans
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/*metabolism/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - RNA Interference
MH  - RNA, Small Interfering
MH  - Tumor Cells, Cultured
MH  - Tumor Suppressor Protein p53/*metabolism
MH  - Ubiquitin-Protein Ligases/genetics/*metabolism
MH  - Ubiquitination
PMC - PMC3609428
MID - NIHMS443106
OID - NLM: NIHMS443106
OID - NLM: PMC3609428
EDAT- 2013/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/23 06:00
PHST- 2011/08/12 [received]
PHST- 2012/04/25 [revised]
PHST- 2013/01/29 [accepted]
AID - S1535-6108(13)00044-5 [pii]
AID - 10.1016/j.ccr.2013.01.025 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):362-75. doi: 10.1016/j.ccr.2013.01.025.

PMID- 23518349
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
PG  - 347-61
LID - 10.1016/j.ccr.2013.01.026 [doi]
LID - S1535-6108(13)00045-7 [pii]
AB  - Imatinib eradicates dividing progenitor cells of chronic myeloid leukemia (CML)
      but does not effectively target nondividing leukemia-initiating cells (LICs);
      thus, the disease often relapse after its discontinuation. We now show that Fbxw7
      plays a pivotal role in maintenance of quiescence in LICs of CML by reducing the 
      level of c-Myc. Abrogation of quiescence in LICs by Fbxw7 ablation increased
      their sensitivity to imatinib, and the combination of Fbxw7 ablation with
      imatinib treatment resulted in a greater depletion of LICs than of normal
      hematopoietic stem cells in mice. Purging of LICs by targeting Fbxw7 to interrupt
      their quiescence and subsequent treatment with imatinib may thus provide the
      basis for a promising therapeutic approach to CML.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Takeishi, Shoichiro
AU  - Takeishi S
AD  - Department of Molecular and Cellular Biology, Medical Institute of Bioregulation,
      Kyushu University, 3-1-1 Maidashi, Fukuoka, Fukuoka 812-8582, Japan.
FAU - Matsumoto, Akinobu
AU  - Matsumoto A
FAU - Onoyama, Ichiro
AU  - Onoyama I
FAU - Naka, Kazuhito
AU  - Naka K
FAU - Hirao, Atsushi
AU  - Hirao A
FAU - Nakayama, Keiichi I
AU  - Nakayama KI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Benzamides)
RN  - 0 (F-Box Proteins)
RN  - 0 (Fbxw7 protein, mouse)
RN  - 0 (Myc protein, mouse)
RN  - 0 (Piperazines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (Pyrimidines)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - BKJ8M8G5HI (imatinib)
RN  - EC 6.3.2.19 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Benzamides/*therapeutic use
MH  - Cell Cycle
MH  - Down-Regulation
MH  - F-Box Proteins/*antagonists & inhibitors/genetics/*metabolism
MH  - Hematopoietic Stem Cells/physiology
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug
      therapy/*metabolism/pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Transgenic
MH  - Neoplastic Stem Cells/physiology
MH  - Piperazines/*therapeutic use
MH  - Protein Kinase Inhibitors/therapeutic use
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Pyrimidines/*therapeutic use
MH  - RNA Interference
MH  - RNA, Small Interfering
MH  - Tumor Suppressor Protein p53/metabolism
MH  - Ubiquitin-Protein Ligases/*antagonists & inhibitors/genetics/*metabolism
EDAT- 2013/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/23 06:00
PHST- 2011/06/29 [received]
PHST- 2012/04/25 [revised]
PHST- 2013/01/22 [accepted]
AID - S1535-6108(13)00045-7 [pii]
AID - 10.1016/j.ccr.2013.01.026 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):347-61. doi: 10.1016/j.ccr.2013.01.026.

PMID- 23518348
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer
      by regulation of androgen receptor transcriptional activity.
PG  - 332-46
LID - 10.1016/j.ccr.2013.02.016 [doi]
LID - S1535-6108(13)00072-X [pii]
AB  - Understanding the mechanism underlying the regulation of the androgen receptor
      (AR), a central player in the development of castration-resistant prostate cancer
      (CRPC), holds promise for overcoming the challenge of treating CRPC. We
      demonstrate that the ubiquitin ligase Siah2 targets a select pool of NCOR1-bound,
      transcriptionally-inactive AR for ubiquitin-dependent degradation, thereby
      promoting expression of select AR target genes implicated in lipid metabolism,
      cell motility, and proliferation. Siah2 is required for prostate cancer cell
      growth under androgen-deprivation conditions in vitro and in vivo, and Siah2
      inhibition promotes prostate cancer regression upon castration. Notably, Siah2
      expression is markedly increased in human CRPCs. Collectively, we find that
      selective regulation of AR transcriptional activity by the ubiquitin ligase Siah2
      is important for CRPC development.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Qi, Jianfei
AU  - Qi J
AD  - Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research
      Institute, La Jolla, CA 92037, USA. jfqi@sbmri.org
FAU - Tripathi, Manisha
AU  - Tripathi M
FAU - Mishra, Rajeev
AU  - Mishra R
FAU - Sahgal, Natasha
AU  - Sahgal N
FAU - Fazli, Ladan
AU  - Fazli L
FAU - Ettinger, Susan
AU  - Ettinger S
FAU - Placzek, William J
AU  - Placzek WJ
FAU - Claps, Giuseppina
AU  - Claps G
FAU - Chung, Leland W K
AU  - Chung LW
FAU - Bowtell, David
AU  - Bowtell D
FAU - Gleave, Martin
AU  - Gleave M
FAU - Bhowmick, Neil
AU  - Bhowmick N
FAU - Ronai, Ze'ev A
AU  - Ronai ZA
LA  - eng
SI  - GEO/GSE38851
GR  - 090532/Z/09/Z/Wellcome Trust/United Kingdom
GR  - CA111515/CA/NCI NIH HHS/United States
GR  - CA154888/CA/NCI NIH HHS/United States
GR  - K99 CA154888/CA/NCI NIH HHS/United States
GR  - P30 CA030199/CA/NCI NIH HHS/United States
GR  - R01 CA111515/CA/NCI NIH HHS/United States
GR  - Canadian Institutes of Health Research/Canada
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AR protein, human)
RN  - 0 (NCOR1 protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Nuclear Receptor Co-Repressor 1)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Ubiquitin)
RN  - EC 6.3.2.19 (Ubiquitin-Protein Ligases)
RN  - EC 6.3.2.19 (seven in absentia proteins)
SB  - IM
CIN - Urol Oncol. 2014 Feb;32(2):210-1. PMID: 24445292
EIN - Cancer Cell. 2013 Jun 10;23(6):853. Fazil, Ladan [corrected to Fazli, Ladan]
MH  - Animals
MH  - Castration
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lipid Metabolism
MH  - Male
MH  - Mice
MH  - Nuclear Proteins/genetics/*metabolism
MH  - Nuclear Receptor Co-Repressor 1/*metabolism
MH  - Prostatic Neoplasms/*genetics/*metabolism
MH  - RNA Interference
MH  - RNA, Small Interfering
MH  - Receptors, Androgen/*metabolism
MH  - Signal Transduction
MH  - *Transcription, Genetic
MH  - Ubiquitin/metabolism
MH  - Ubiquitin-Protein Ligases/genetics/*metabolism
PMC - PMC3750989
MID - NIHMS451129
OID - NLM: NIHMS451129
OID - NLM: PMC3750989
EDAT- 2013/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/23 06:00
PHST- 2012/06/08 [received]
PHST- 2012/10/22 [revised]
PHST- 2013/02/13 [accepted]
AID - S1535-6108(13)00072-X [pii]
AID - 10.1016/j.ccr.2013.02.016 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):332-46. doi: 10.1016/j.ccr.2013.02.016.

PMID- 23518347
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Macrophage regulation of tumor responses to anticancer therapies.
PG  - 277-86
LID - 10.1016/j.ccr.2013.02.013 [doi]
LID - S1535-6108(13)00069-X [pii]
AB  - Tumor-associated macrophages (TAMs) promote key processes in tumor progression,
      like angiogenesis, immunosuppression, invasion, and metastasis. Increasing
      studies have also shown that TAMs can either enhance or antagonize the antitumor 
      efficacy of cytotoxic chemotherapy, cancer-cell targeting antibodies, and
      immunotherapeutic agents--depending on the type of treatment and tumor model.
      TAMs also drive reparative mechanisms in tumors after radiotherapy or treatment
      with vascular-targeting agents. Here, we discuss the biological significance and 
      clinical implications of these findings, with an emphasis on novel approaches
      that effectively target TAMs to increase the efficacy of such therapies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - De Palma, Michele
AU  - De Palma M
AD  - The Swiss Institute for Experimental Cancer Research (ISREC), School of Life
      Sciences, Swiss Federal Institute of Technology Lausanne (EPFL), CH-1015
      Lausanne, Switzerland. michele.depalma@epfl.ch
FAU - Lewis, Claire E
AU  - Lewis CE
LA  - eng
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Animals
MH  - Antibodies, Neoplasm/immunology
MH  - Antineoplastic Agents/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Disease Progression
MH  - Humans
MH  - Immunotherapy
MH  - Macrophage Activation
MH  - Macrophages/*immunology
MH  - Neoplasms/drug therapy/*immunology/radiotherapy/*therapy
MH  - Neovascularization, Pathologic/drug therapy
EDAT- 2013/03/23 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/23 06:00
PHST- 2012/12/10 [received]
PHST- 2013/01/21 [revised]
PHST- 2013/02/15 [accepted]
AID - S1535-6108(13)00069-X [pii]
AID - 10.1016/j.ccr.2013.02.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):277-86. doi: 10.1016/j.ccr.2013.02.013.

PMID- 23518346
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20140926
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.
PG  - 274-6
LID - 10.1016/j.ccr.2013.03.005 [doi]
LID - S1535-6108(13)00084-6 [pii]
AB  - The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that
      they have lost their normal catalytic activity and gained a novel function to
      produce R-2-hydroxyglutarate (R-2-HG). A recent study now shows that R-2-HG can
      reversibly promote leukemogenesis in vitro, suggesting a therapeutic potential of
      targeting mutant IDH1 and IDH2.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ye, Dan
AU  - Ye D
AD  - Key Laboratory of Molecular Medicine of Ministry of Education and Institutes of
      Biomedical Sciences, Shanghai Medical College, College of Life Science, Fudan
      University, Shanghai 200032, China.
FAU - Ma, Shenghong
AU  - Ma S
FAU - Xiong, Yue
AU  - Xiong Y
FAU - Guan, Kun-Liang
AU  - Guan KL
LA  - eng
GR  - P30 CA016086/CA/NCI NIH HHS/United States
GR  - R01 CA108941/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Science. 2013 Mar 29;339(6127):1621-5. PMID: 23393090
PMC - PMC3652525
MID - NIHMS456879
OID - NLM: NIHMS456879
OID - NLM: PMC3652525
EDAT- 2013/03/23 06:00
MHDA- 2013/03/23 06:01
CRDT- 2013/03/23 06:00
AID - S1535-6108(13)00084-6 [pii]
AID - 10.1016/j.ccr.2013.03.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):274-6. doi: 10.1016/j.ccr.2013.03.005.

PMID- 23518345
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130322
DCOM- 20130521
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Tumor dissemination: an EMT affair.
PG  - 272-3
LID - 10.1016/j.ccr.2013.03.004 [doi]
LID - S1535-6108(13)00083-4 [pii]
AB  - A recent paper reports that circulating tumor cells (CTCs) from metastatic breast
      cancer patients exhibit heterogeneous epithelial and mesenchymal phenotypes and
      that CTCs display higher frequencies of partial or full-blown mesenchymal
      phenotype than carcinoma cells within primary tumors. Mesenchymal-like CTCs are
      also elevated in patients who are refractory to therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Thiery, Jean Paul
AU  - Thiery JP
AD  - Department of Biochemistry, National University of Singapore, Singapore 117599.
      jpthiery@imcb.a-star.edu.sg
FAU - Lim, Chwee Teck
AU  - Lim CT
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Science. 2013 Feb 1;339(6119):580-4. PMID: 23372014
EDAT- 2013/03/23 06:00
MHDA- 2013/03/23 06:01
CRDT- 2013/03/23 06:00
AID - S1535-6108(13)00083-4 [pii]
AID - 10.1016/j.ccr.2013.03.004 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):272-3. doi: 10.1016/j.ccr.2013.03.004.

PMID- 23518344
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20140319
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Interweaving the strands: beta-catenin, an HIV co-receptor, and Schwann cell
      tumors.
PG  - 269-71
LID - 10.1016/j.ccr.2013.03.001 [doi]
LID - S1535-6108(13)00081-0 [pii]
AB  - WNT/beta-catenin signaling is critical to the development of many cancer types. A
      paper by Mo and colleagues in a recent issue of Cell shows that autocrine
      CXCL12/CXCR4 chemokine signaling activates beta-catenin signaling in a rare
      peripheral nerve sarcoma. Together with the availability of small molecules
      targeting CXCR4, this finding suggests new avenues for cancer therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Largaespada, David
AU  - Largaespada D
AD  - Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
      larga002@umn.edu
FAU - Ratner, Nancy
AU  - Ratner N
LA  - eng
GR  - P50 NS057531/NS/NINDS NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cell. 2013 Feb 28;152(5):1077-90. PMID: 23434321
PMC - PMC3635484
MID - NIHMS456878
OID - NLM: NIHMS456878
OID - NLM: PMC3635484
EDAT- 2013/03/23 06:00
MHDA- 2013/03/23 06:01
CRDT- 2013/03/23 06:00
PHST- 2013/03/18 [aheadofprint]
AID - S1535-6108(13)00081-0 [pii]
AID - 10.1016/j.ccr.2013.03.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):269-71. doi: 10.1016/j.ccr.2013.03.001.

PMID- 23518343
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130322
DCOM- 20130521
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Selective blockade of transport via SERCA inhibition: the answer for oncogenic
      forms of Notch?
PG  - 267-9
LID - 10.1016/j.ccr.2013.02.020 [doi]
LID - S1535-6108(13)00076-7 [pii]
AB  - NOTCH1, which is frequently mutated in T cell acute lymphoblastic leukemia, has
      been an elusive therapeutic target. In this issue of Cancer Cell, Roti and
      colleagues demonstrate that inhibiting SERCA calcium pumps preferentially impairs
      the maturation of the most common class of oncogenic Notch1 mutants, thus
      uncovering a potential therapeutic avenue.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ilagan, Ma Xenia G
AU  - Ilagan MX
AD  - Department of Developmental Biology, Washington University School of Medicine,
      St. Louis, MO 63110, USA. ilaganmg@wustl.edu
FAU - Kopan, Raphael
AU  - Kopan R
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Mar 18;23(3):390-405. PMID: 23434461
EDAT- 2013/03/23 06:00
MHDA- 2013/03/23 06:01
CRDT- 2013/03/23 06:00
AID - S1535-6108(13)00076-7 [pii]
AID - 10.1016/j.ccr.2013.02.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):267-9. doi: 10.1016/j.ccr.2013.02.020.

PMID- 23518342
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130322
DCOM- 20130521
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - ROS links glucose metabolism to breast cancer stem cell and EMT phenotype.
PG  - 265-7
LID - 10.1016/j.ccr.2013.02.021 [doi]
LID - S1535-6108(13)00077-9 [pii]
AB  - Cancer stem cells display an epithelial-mesenchymal transition phenotype and are 
      resistant to current therapies. In this issue of Cancer Cell, Dong and colleagues
      demonstrate that these phenotypes in basal-like breast cancer are promoted by a
      metabolic switch to glucose metabolism, resulting in decreased reactive oxygen
      species levels.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Schieber, Michael S
AU  - Schieber MS
AD  - Division of Pulmonary and Critical Care Medicine, Department of Medicine,
      Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
FAU - Chandel, Navdeep S
AU  - Chandel NS
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Mar 18;23(3):316-31. PMID: 23453623
EDAT- 2013/03/23 06:00
MHDA- 2013/03/23 06:01
CRDT- 2013/03/23 06:00
AID - S1535-6108(13)00077-9 [pii]
AID - 10.1016/j.ccr.2013.02.021 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):265-7. doi: 10.1016/j.ccr.2013.02.021.

PMID- 23518341
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130322
DCOM- 20130521
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Targeting oxidative phosphorylation: why, when, and how.
PG  - 263-4
LID - 10.1016/j.ccr.2013.02.015 [doi]
LID - S1535-6108(13)00071-8 [pii]
AB  - In this issue of Cancer Cell, Vazquez and colleagues report reduced glycolysis
      and increased oxidative phosphorylation in certain melanomas, revealing metabolic
      plasticity rather than stable Warburg pathophysiology. Furthermore, Haq and
      colleagues (also in this issue of Cancer Cell) show situations where increased
      oxidative phosphorylation is required for melanomas to survive inhibition of
      B-RAF, suggesting investigation of therapeutic combinations of B-RAF inhibitors
      with biguanides.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Pollak, Michael
AU  - Pollak M
AD  - Department of Oncology, McGill University, Montreal, QC H3T1E2, Canada.
      michael.pollak@mcgill.ca
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Mar 18;23(3):302-15. PMID: 23477830
CON - Cancer Cell. 2013 Mar 18;23(3):287-301. PMID: 23416000
EDAT- 2013/03/23 06:00
MHDA- 2013/03/23 06:01
CRDT- 2013/03/23 06:00
AID - S1535-6108(13)00071-8 [pii]
AID - 10.1016/j.ccr.2013.02.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):263-4. doi: 10.1016/j.ccr.2013.02.015.

PMID- 23477830
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF.
PG  - 302-15
LID - 10.1016/j.ccr.2013.02.003 [doi]
LID - S1535-6108(13)00067-6 [pii]
AB  - Activating mutations in BRAF are the most common genetic alterations in melanoma.
      Inhibition of BRAF by small molecules leads to cell-cycle arrest and apoptosis.
      We show here that BRAF inhibition also induces an oxidative phosphorylation gene 
      program, mitochondrial biogenesis, and the increased expression of the
      mitochondrial master regulator, PGC1alpha. We further show that a target of BRAF,
      the melanocyte lineage factor MITF, directly regulates the expression of
      PGC1alpha. Melanomas with activation of the BRAF/MAPK pathway have suppressed
      levels of MITF and PGC1alpha and decreased oxidative metabolism. Conversely,
      treatment of BRAF-mutated melanomas with BRAF inhibitors renders them addicted to
      oxidative phosphorylation. Our data thus identify an adaptive metabolic program
      that limits the efficacy of BRAF inhibitors.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Haq, Rizwan
AU  - Haq R
AD  - Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, 55 
      Fruit Street, Boston, MA 02114, USA.
FAU - Shoag, Jonathan
AU  - Shoag J
FAU - Andreu-Perez, Pedro
AU  - Andreu-Perez P
FAU - Yokoyama, Satoru
AU  - Yokoyama S
FAU - Edelman, Hannah
AU  - Edelman H
FAU - Rowe, Glenn C
AU  - Rowe GC
FAU - Frederick, Dennie T
AU  - Frederick DT
FAU - Hurley, Aeron D
AU  - Hurley AD
FAU - Nellore, Abhinav
AU  - Nellore A
FAU - Kung, Andrew L
AU  - Kung AL
FAU - Wargo, Jennifer A
AU  - Wargo JA
FAU - Song, Jun S
AU  - Song JS
FAU - Fisher, David E
AU  - Fisher DE
FAU - Arany, Zolt
AU  - Arany Z
FAU - Widlund, Hans R
AU  - Widlund HR
LA  - eng
SI  - GEO/GSE38007
GR  - P01 CA163222/CA/NCI NIH HHS/United States
GR  - P50 CA093683/CA/NCI NIH HHS/United States
GR  - P50CA093683/CA/NCI NIH HHS/United States
GR  - R01 AR043369/AR/NIAMS NIH HHS/United States
GR  - R01 AR043369-16/AR/NIAMS NIH HHS/United States
GR  - R01 CA163336/CA/NCI NIH HHS/United States
GR  - R01 HL094499/HL/NHLBI NIH HHS/United States
GR  - R01CA163336/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130307
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (Indoles)
RN  - 0 (Microphthalmia-Associated Transcription Factor)
RN  - 0 (PLX 4720)
RN  - 0 (PLX4032)
RN  - 0 (PPARGC1A protein, human)
RN  - 0 (RNA, Messenger)
RN  - 0 (Sulfonamides)
RN  - 0 (Transcription Factors)
RN  - EC 2.7.11.1 (BRAF protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins B-raf)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
CIN - Nat Rev Cancer. 2013 May;13(5):296-7. PMID: 23562975
CIN - Cancer Cell. 2013 Mar 18;23(3):263-4. PMID: 23518341
MH  - Apoptosis
MH  - Cell Line, Tumor
MH  - Gene Expression Regulation, Neoplastic
MH  - Heat-Shock Proteins/genetics/*metabolism
MH  - Humans
MH  - Indoles/pharmacology
MH  - Melanocytes/metabolism
MH  - Melanoma/genetics/*metabolism
MH  - Microphthalmia-Associated Transcription Factor/*metabolism
MH  - Mitochondria/metabolism
MH  - Mitogen-Activated Protein Kinases/metabolism
MH  - Mutation
MH  - Oxidative Phosphorylation
MH  - Proto-Oncogene Proteins B-raf/antagonists & inhibitors/genetics/*metabolism
MH  - RNA, Messenger/biosynthesis
MH  - Signal Transduction
MH  - Sulfonamides/pharmacology
MH  - Transcription Factors/genetics/*metabolism
PMC - PMC3635826
MID - NIHMS444425
OID - NLM: NIHMS444425
OID - NLM: PMC3635826
EDAT- 2013/03/13 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/13 06:00
PHST- 2012/05/21 [received]
PHST- 2012/11/27 [revised]
PHST- 2013/02/05 [accepted]
PHST- 2013/03/07 [aheadofprint]
AID - S1535-6108(13)00067-6 [pii]
AID - 10.1016/j.ccr.2013.02.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):302-15. doi: 10.1016/j.ccr.2013.02.003. Epub 2013 
      Mar 7.

PMID- 23453624
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20140220
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic 
      cell plasticity and cancer.
PG  - 406-20
LID - 10.1016/j.ccr.2013.01.023 [doi]
LID - S1535-6108(13)00043-3 [pii]
AB  - Oncogenic Kras activates a plethora of signaling pathways, but our understanding 
      of critical Ras effectors is still very limited. We show that cell-autonomous
      phosphoinositide 3-kinase (PI3K) and 3-phosphoinositide-dependent protein kinase 
      1 (PDK1), but not Craf, are key effectors of oncogenic Kras in the pancreas,
      mediating cell plasticity, acinar-to-ductal metaplasia (ADM), and pancreatic
      ductal adenocarcinoma (PDAC) formation. This contrasts with Kras-driven non-small
      cell lung cancer, where signaling via Craf, but not PDK1, is an essential
      tumor-initiating event. These in vivo genetic studies together with pharmacologic
      treatment studies in models of human ADM and PDAC demonstrate tissue-specific
      differences of oncogenic Kras signaling and define PI3K/PDK1 as a suitable target
      for therapeutic intervention specifically in PDAC.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Eser, Stefan
AU  - Eser S
AD  - Department of Internal Medicine 2, Technische Universitat Munchen, Ismaningerstr.
      22, 81675 Munchen, Germany.
FAU - Reiff, Nina
AU  - Reiff N
FAU - Messer, Marlena
AU  - Messer M
FAU - Seidler, Barbara
AU  - Seidler B
FAU - Gottschalk, Kathleen
AU  - Gottschalk K
FAU - Dobler, Melanie
AU  - Dobler M
FAU - Hieber, Maren
AU  - Hieber M
FAU - Arbeiter, Andreas
AU  - Arbeiter A
FAU - Klein, Sabine
AU  - Klein S
FAU - Kong, Bo
AU  - Kong B
FAU - Michalski, Christoph W
AU  - Michalski CW
FAU - Schlitter, Anna Melissa
AU  - Schlitter AM
FAU - Esposito, Irene
AU  - Esposito I
FAU - Kind, Alexander J
AU  - Kind AJ
FAU - Rad, Lena
AU  - Rad L
FAU - Schnieke, Angelika E
AU  - Schnieke AE
FAU - Baccarini, Manuela
AU  - Baccarini M
FAU - Alessi, Dario R
AU  - Alessi DR
FAU - Rad, Roland
AU  - Rad R
FAU - Schmid, Roland M
AU  - Schmid RM
FAU - Schneider, Gunter
AU  - Schneider G
FAU - Saur, Dieter
AU  - Saur D
LA  - eng
GR  - MC_U127015387/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130228
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0
      (2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylth
      ieno(3,2-d)pyrimidine)
RN  - 0 (Cyclin-Dependent Kinase Inhibitor p16)
RN  - 0 (Indazoles)
RN  - 0 (KRAS protein, human)
RN  - 0 (Lithostathine)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (REG1A protein, human)
RN  - 0 (Sulfonamides)
RN  - 0 (TNF Receptor-Associated Factor 3)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.11.1 (3-Phosphoinositide-Dependent Protein Kinases)
RN  - EC 2.7.11.1 (PDPK1 protein, human)
RN  - EC 2.7.11.1 (Pdpk1 protein, mouse)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 3.6.5.2 (ras Proteins)
SB  - IM
CIN - Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):320-1. PMID: 23746401
MH  - 3-Phosphoinositide-Dependent Protein Kinases
MH  - Adenocarcinoma/genetics/metabolism/pathology
MH  - Animals
MH  - Carcinoma, Pancreatic Ductal/genetics/metabolism/pathology
MH  - Cell Proliferation
MH  - Cell Transformation, Neoplastic/genetics/metabolism
MH  - Cyclin-Dependent Kinase Inhibitor p16/genetics/metabolism
MH  - Enzyme Activation
MH  - Humans
MH  - Indazoles/pharmacology
MH  - Lithostathine/metabolism
MH  - Metaplasia
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Neoplasm Transplantation
MH  - Pancreatic Neoplasms/genetics/*metabolism/pathology
MH  - Phosphatidylinositol 3-Kinases/*metabolism
MH  - Protein-Serine-Threonine Kinases/*metabolism
MH  - Proto-Oncogene Proteins/*metabolism
MH  - Signal Transduction
MH  - Sulfonamides/pharmacology
MH  - TNF Receptor-Associated Factor 3/*metabolism
MH  - Transplantation, Heterologous
MH  - Tumor Cells, Cultured
MH  - ras Proteins/*metabolism
EDAT- 2013/03/05 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/05 06:00
PHST- 2012/10/04 [received]
PHST- 2012/12/27 [revised]
PHST- 2013/01/30 [accepted]
PHST- 2013/02/28 [aheadofprint]
AID - S1535-6108(13)00043-3 [pii]
AID - 10.1016/j.ccr.2013.01.023 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):406-20. doi: 10.1016/j.ccr.2013.01.023. Epub 2013 
      Feb 28.

PMID- 23453623
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Loss of FBP1 by Snail-mediated repression provides metabolic advantages in
      basal-like breast cancer.
PG  - 316-31
LID - 10.1016/j.ccr.2013.01.022 [doi]
LID - S1535-6108(13)00042-1 [pii]
AB  - The epithelial-mesenchymal transition (EMT) enhances cancer invasiveness and
      confers tumor cells with cancer stem cell (CSC)-like characteristics. We show
      that the Snail-G9a-Dnmt1 complex, which is critical for E-cadherin promoter
      silencing, is also required for the promoter methylation of
      fructose-1,6-biphosphatase (FBP1) in basal-like breast cancer (BLBC). Loss of
      FBP1 induces glycolysis and results in increased glucose uptake, macromolecule
      biosynthesis, formation of tetrameric PKM2, and maintenance of ATP production
      under hypoxia. Loss of FBP1 also inhibits oxygen consumption and reactive oxygen 
      species production by suppressing mitochondrial complex I activity; this
      metabolic reprogramming results in an increased CSC-like property and
      tumorigenicity by enhancing the interaction of beta-catenin with T-cell factor.
      Our study indicates that the loss of FBP1 is a critical oncogenic event in EMT
      and BLBC.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Dong, Chenfang
AU  - Dong C
AD  - Department of Molecular and Cellular Biochemistry, The University of Kentucky,
      College of Medicine, Lexington, KY 40506, USA.
FAU - Yuan, Tingting
AU  - Yuan T
FAU - Wu, Yadi
AU  - Wu Y
FAU - Wang, Yifan
AU  - Wang Y
FAU - Fan, Teresa W M
AU  - Fan TW
FAU - Miriyala, Sumitra
AU  - Miriyala S
FAU - Lin, Yiwei
AU  - Lin Y
FAU - Yao, Jun
AU  - Yao J
FAU - Shi, Jian
AU  - Shi J
FAU - Kang, Tiebang
AU  - Kang T
FAU - Lorkiewicz, Pawel
AU  - Lorkiewicz P
FAU - St Clair, Daret
AU  - St Clair D
FAU - Hung, Mien-Chie
AU  - Hung MC
FAU - Evers, B Mark
AU  - Evers BM
FAU - Zhou, Binhua P
AU  - Zhou BP
LA  - eng
SI  - GEO/GSE41158
GR  - 1R01ES022191-01/ES/NIEHS NIH HHS/United States
GR  - CA049797/CA/NCI NIH HHS/United States
GR  - CA073599/CA/NCI NIH HHS/United States
GR  - CA118434-01A2/CA/NCI NIH HHS/United States
GR  - CA125454/CA/NCI NIH HHS/United States
GR  - P20CA1530343/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P30 CA177558/CA/NCI NIH HHS/United States
GR  - R01 CA125454/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130228
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Carrier Proteins)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Membrane Proteins)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (TCF Transcription Factors)
RN  - 0 (Thyroid Hormones)
RN  - 0 (Transcription Factors)
RN  - 0 (beta Catenin)
RN  - 0 (snail family transcription factors)
RN  - 0 (thyroid hormone-binding proteins)
RN  - EC 1.6.5.3 (Electron Transport Complex I)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase)
RN  - EC 2.1.1.37 (DNA (cytosine-5-)-methyltransferase 1)
RN  - EC 2.1.1.43 (EHMT2 protein, human)
RN  - EC 2.1.1.43 (Histone-Lysine N-Methyltransferase)
RN  - EC 3.1.3.11 (Fructose-Bisphosphatase)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
CIN - Cancer Cell. 2013 Mar 18;23(3):265-7. PMID: 23518342
MH  - Animals
MH  - Breast Neoplasms/*metabolism/pathology
MH  - Carrier Proteins/biosynthesis
MH  - Cell Hypoxia
MH  - Cell Line, Tumor
MH  - DNA (Cytosine-5-)-Methyltransferase
MH  - DNA Methylation
MH  - Electron Transport Complex I/metabolism
MH  - *Epithelial-Mesenchymal Transition
MH  - Female
MH  - Fructose-Bisphosphatase/genetics/*metabolism
MH  - Glucose/metabolism
MH  - Glycolysis/genetics
MH  - Histocompatibility Antigens
MH  - Histone-Lysine N-Methyltransferase
MH  - Humans
MH  - Membrane Proteins/biosynthesis
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Mice, SCID
MH  - Neoplasm Invasiveness
MH  - Neoplastic Stem Cells/*metabolism
MH  - Oxidative Phosphorylation
MH  - Oxygen Consumption/genetics
MH  - Promoter Regions, Genetic
MH  - Reactive Oxygen Species/metabolism
MH  - TCF Transcription Factors/metabolism
MH  - Thyroid Hormones/biosynthesis
MH  - Transcription Factors/*metabolism
MH  - beta Catenin/metabolism
PMC - PMC3703516
MID - NIHMS442462
OID - NLM: NIHMS442462
OID - NLM: PMC3703516
EDAT- 2013/03/05 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/03/05 06:00
PHST- 2012/04/01 [received]
PHST- 2012/09/25 [revised]
PHST- 2013/01/29 [accepted]
PHST- 2013/02/28 [aheadofprint]
AID - S1535-6108(13)00042-1 [pii]
AID - 10.1016/j.ccr.2013.01.022 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):316-31. doi: 10.1016/j.ccr.2013.01.022. Epub 2013 
      Feb 28.

PMID- 23447819
OWN - NLM
STAT- MEDLINE
DA  - 20130227
DCOM- 20130326
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Retraction. Ras modulates Myc activity to repress thrombospondin-1 expression and
      increase tumor angiogenesis.
PG  - 129
LA  - eng
PT  - Retraction of Publication
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
SB  - IM
ROF - Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Cancer Cell. 2003
      Mar;3(3):219-31. PMID: 12676581
EDAT- 2013/03/01 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/03/01 06:00
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):129.

PMID- 23434461
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1
      mutated cancer.
PG  - 390-405
LID - 10.1016/j.ccr.2013.01.015 [doi]
LID - S1535-6108(13)00037-8 [pii]
AB  - Notch1 is a rational therapeutic target in several human cancers, but as a
      transcriptional regulator, it poses a drug discovery challenge. To identify
      Notch1 modulators, we performed two cell-based, high-throughput screens for
      small-molecule inhibitors and cDNA enhancers of a NOTCH1 allele bearing a
      leukemia-associated mutation. Sarco/endoplasmic reticulum calcium ATPase (SERCA) 
      channels emerged at the intersection of these complementary screens. SERCA
      inhibition preferentially impairs the maturation and activity of mutated Notch1
      receptors and induces a G0/G1 arrest in NOTCH1-mutated human leukemia cells. A
      small-molecule SERCA inhibitor has on-target activity in two mouse models of
      human leukemia and interferes with Notch signaling in Drosophila. These studies
      "credential" SERCA as a therapeutic target in cancers associated with NOTCH1
      mutations.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Roti, Giovanni
AU  - Roti G
AD  - Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215,
      USA.
FAU - Carlton, Anne
AU  - Carlton A
FAU - Ross, Kenneth N
AU  - Ross KN
FAU - Markstein, Michele
AU  - Markstein M
FAU - Pajcini, Kostandin
AU  - Pajcini K
FAU - Su, Angela H
AU  - Su AH
FAU - Perrimon, Norbert
AU  - Perrimon N
FAU - Pear, Warren S
AU  - Pear WS
FAU - Kung, Andrew L
AU  - Kung AL
FAU - Blacklow, Stephen C
AU  - Blacklow SC
FAU - Aster, Jon C
AU  - Aster JC
FAU - Stegmaier, Kimberly
AU  - Stegmaier K
LA  - eng
GR  - 5 UL1 RR025758/RR/NCRR NIH HHS/United States
GR  - P01 CA 068484-11A1/CA/NCI NIH HHS/United States
GR  - P30 CA016520/CA/NCI NIH HHS/United States
GR  - R01 CA 092433/CA/NCI NIH HHS/United States
GR  - R01 CA092433/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130221
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Calcium Channels)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Notch1 protein, mouse)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Small Molecule Libraries)
RN  - 67526-95-8 (Thapsigargin)
RN  - EC 3.6.3.8 (Sarcoplasmic Reticulum Calcium-Transporting ATPases)
SB  - IM
CIN - Cancer Cell. 2013 Mar 18;23(3):267-9. PMID: 23518343
MH  - Alleles
MH  - Animals
MH  - Calcium Channels/genetics
MH  - Cell Line, Tumor
MH  - Drosophila/genetics/metabolism
MH  - Drug Screening Assays, Antitumor
MH  - Enzyme Inhibitors/pharmacology
MH  - Female
MH  - G1 Phase Cell Cycle Checkpoints/genetics
MH  - Gene Library
MH  - High-Throughput Screening Assays
MH  - Humans
MH  - Leukemia/*genetics/*metabolism
MH  - Mice
MH  - Mice, SCID
MH  - Mutation
MH  - Neoplasm Transplantation
MH  - Receptor, Notch1/antagonists & inhibitors/*genetics
MH  - Sarcoplasmic Reticulum Calcium-Transporting ATPases/antagonists &
      inhibitors/*genetics
MH  - Signal Transduction/genetics
MH  - Small Molecule Libraries
MH  - Thapsigargin/pharmacology
MH  - Transplantation, Heterologous
PMC - PMC3709972
MID - NIHMS440887
OID - NLM: NIHMS440887
OID - NLM: PMC3709972
EDAT- 2013/02/26 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/02/26 06:00
PHST- 2012/03/15 [received]
PHST- 2012/11/30 [revised]
PHST- 2013/01/22 [accepted]
PHST- 2013/02/21 [aheadofprint]
AID - S1535-6108(13)00037-8 [pii]
AID - 10.1016/j.ccr.2013.01.015 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):390-405. doi: 10.1016/j.ccr.2013.01.015. Epub 2013
      Feb 21.

PMID- 23416000
OWN - NLM
STAT- MEDLINE
DA  - 20130322
DCOM- 20130521
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 3
DP  - 2013 Mar 18
TI  - PGC1alpha expression defines a subset of human melanoma tumors with increased
      mitochondrial capacity and resistance to oxidative stress.
PG  - 287-301
LID - 10.1016/j.ccr.2012.11.020 [doi]
LID - S1535-6108(13)00034-2 [pii]
AB  - Cancer cells reprogram their metabolism using different strategies to meet energy
      and anabolic demands to maintain growth and survival. Understanding the molecular
      and genetic determinants of these metabolic programs is critical to successfully 
      exploit them for therapy. Here, we report that the oncogenic melanocyte
      lineage-specification transcription factor MITF drives PGC1alpha (PPARGC1A)
      overexpression in a subset of human melanomas and derived cell lines.
      Functionally, PGC1alpha positive melanoma cells exhibit increased mitochondrial
      energy metabolism and reactive oxygen species (ROS) detoxification capacities
      that enable survival under oxidative stress conditions. Conversely, PGC1alpha
      negative melanoma cells are more glycolytic and sensitive to ROS-inducing drugs. 
      These results demonstrate that differences in PGC1alpha levels in melanoma tumors
      have a profound impact in their metabolism, biology, and drug sensitivity.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Vazquez, Francisca
AU  - Vazquez F
AD  - Department of Cancer Biology, Dana-Farber Cancer Institute and Department of Cell
      Biology, Harvard Medical School, Boston, MA 02115, USA.
FAU - Lim, Ji-Hong
AU  - Lim JH
FAU - Chim, Helen
AU  - Chim H
FAU - Bhalla, Kavita
AU  - Bhalla K
FAU - Girnun, Geoff
AU  - Girnun G
FAU - Pierce, Kerry
AU  - Pierce K
FAU - Clish, Clary B
AU  - Clish CB
FAU - Granter, Scott R
AU  - Granter SR
FAU - Widlund, Hans R
AU  - Widlund HR
FAU - Spiegelman, Bruce M
AU  - Spiegelman BM
FAU - Puigserver, Pere
AU  - Puigserver P
LA  - eng
SI  - GEO/GSE36879
GR  - P30 DK057521/DK/NIDDK NIH HHS/United States
GR  - P50 CA093683/CA/NCI NIH HHS/United States
GR  - P50CA093683/CA/NCI NIH HHS/United States
GR  - R01 CA169919/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130214
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Heat-Shock Proteins)
RN  - 0 (MITF protein, human)
RN  - 0 (Microphthalmia-Associated Transcription Factor)
RN  - 0 (PPARGC1A protein, human)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Reactive Oxygen Species)
RN  - 0 (Transcription Factors)
SB  - IM
CIN - Cancer Cell. 2013 Mar 18;23(3):263-4. PMID: 23518341
CIN - Nat Rev Cancer. 2013 Apr;13(4):222. PMID: 23446548
MH  - Animals
MH  - Apoptosis
MH  - Cell Line, Tumor
MH  - Energy Metabolism
MH  - HEK293 Cells
MH  - Heat-Shock Proteins/genetics/*metabolism
MH  - Humans
MH  - Melanocytes/*metabolism
MH  - Melanoma/*metabolism
MH  - Mice
MH  - Microphthalmia-Associated Transcription Factor/metabolism
MH  - Mitochondria/*metabolism
MH  - *Oxidative Stress
MH  - Oxygen Consumption
MH  - RNA Interference
MH  - RNA, Small Interfering
MH  - Reactive Oxygen Species/metabolism
MH  - Transcription Factors/genetics/*metabolism
PMC - PMC3708305
MID - NIHMS487899
OID - NLM: NIHMS487899
OID - NLM: PMC3708305
EDAT- 2013/02/19 06:00
MHDA- 2013/05/23 06:00
CRDT- 2013/02/19 06:00
PHST- 2012/03/30 [received]
PHST- 2012/08/03 [revised]
PHST- 2012/11/30 [accepted]
PHST- 2013/02/14 [aheadofprint]
AID - S1535-6108(13)00034-2 [pii]
AID - 10.1016/j.ccr.2012.11.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Mar 18;23(3):287-301. doi: 10.1016/j.ccr.2012.11.020. Epub 2013
      Feb 14.

PMID- 23410977
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Role of macrophage targeting in the antitumor activity of trabectedin.
PG  - 249-62
LID - 10.1016/j.ccr.2013.01.008 [doi]
LID - S1535-6108(13)00033-0 [pii]
AB  - There is widespread interest in macrophages as a therapeutic target in cancer.
      Here, we demonstrate that trabectedin, a recently approved chemotherapeutic
      agent, induces rapid apoptosis exclusively in mononuclear phagocytes. In four
      mouse tumor models, trabectedin caused selective depletion of
      monocytes/macrophages in blood, spleens, and tumors, with an associated reduction
      of angiogenesis. By using trabectedin-resistant tumor cells and myeloid cell
      transfer or depletion experiments, we demonstrate that cytotoxicity on
      mononuclear phagocytes is a key component of its antitumor activity. Monocyte
      depletion, including tumor-associated macrophages, was observed in treated tumor 
      patients. Trabectedin activates caspase-8-dependent apoptosis; selectivity for
      monocytes versus neutrophils and lymphocytes is due to differential expression of
      signaling and decoy TRAIL receptors. This unexpected property may be exploited in
      different therapeutic strategies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Germano, Giovanni
AU  - Germano G
AD  - Department Immunology and Inflammation, IRCCS Clinical and Research Institute
      Humanitas, 20089 Rozzano, Milan, Italy.
FAU - Frapolli, Roberta
AU  - Frapolli R
FAU - Belgiovine, Cristina
AU  - Belgiovine C
FAU - Anselmo, Achille
AU  - Anselmo A
FAU - Pesce, Samantha
AU  - Pesce S
FAU - Liguori, Manuela
AU  - Liguori M
FAU - Erba, Eugenio
AU  - Erba E
FAU - Uboldi, Sarah
AU  - Uboldi S
FAU - Zucchetti, Massimo
AU  - Zucchetti M
FAU - Pasqualini, Fabio
AU  - Pasqualini F
FAU - Nebuloni, Manuela
AU  - Nebuloni M
FAU - van Rooijen, Nico
AU  - van Rooijen N
FAU - Mortarini, Roberta
AU  - Mortarini R
FAU - Beltrame, Luca
AU  - Beltrame L
FAU - Marchini, Sergio
AU  - Marchini S
FAU - Fuso Nerini, Ilaria
AU  - Fuso Nerini I
FAU - Sanfilippo, Roberta
AU  - Sanfilippo R
FAU - Casali, Paolo G
AU  - Casali PG
FAU - Pilotti, Silvana
AU  - Pilotti S
FAU - Galmarini, Carlos M
AU  - Galmarini CM
FAU - Anichini, Andrea
AU  - Anichini A
FAU - Mantovani, Alberto
AU  - Mantovani A
FAU - D'Incalci, Maurizio
AU  - D'Incalci M
FAU - Allavena, Paola
AU  - Allavena P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - 0 (Dioxoles)
RN  - 0 (Tetrahydroisoquinolines)
RN  - 114899-77-3 (trabectedin)
RN  - EC 3.4.22.- (Caspase 8)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents, Alkylating/*therapeutic use
MH  - Apoptosis/drug effects
MH  - Blotting, Western
MH  - Carcinoma, Lewis Lung/*drug therapy/metabolism/pathology
MH  - Caspase 8/metabolism
MH  - Cell Proliferation
MH  - Dioxoles/*therapeutic use
MH  - Female
MH  - Fibrosarcoma/*drug therapy/metabolism/pathology
MH  - Flow Cytometry
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Macrophages/*drug effects/metabolism/pathology
MH  - Mice
MH  - Monocytes/drug effects/metabolism/pathology
MH  - Myeloid Cells/drug effects/metabolism/pathology
MH  - Neovascularization, Pathologic/prevention & control
MH  - Ovarian Neoplasms/*drug therapy/metabolism/pathology
MH  - Phagocytes/drug effects/metabolism/pathology
MH  - Signal Transduction/drug effects
MH  - Tetrahydroisoquinolines/*therapeutic use
MH  - Tumor Cells, Cultured
EDAT- 2013/02/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/16 06:00
PHST- 2011/07/07 [received]
PHST- 2012/11/23 [revised]
PHST- 2013/01/15 [accepted]
AID - S1535-6108(13)00033-0 [pii]
AID - 10.1016/j.ccr.2013.01.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

PMID- 23410976
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma
      multiforme.
PG  - 238-48
LID - 10.1016/j.ccr.2013.01.007 [doi]
LID - S1535-6108(13)00032-9 [pii]
AB  - Significant endeavor has been applied to identify functional therapeutic targets 
      in glioblastoma (GBM) to halt the growth of this aggressive cancer. We show that 
      the receptor tyrosine kinase EphA3 is frequently overexpressed in GBM and, in
      particular, in the most aggressive mesenchymal subtype. Importantly, EphA3 is
      highly expressed on the tumor-initiating cell population in glioma and appears
      critically involved in maintaining tumor cells in a less differentiated state by 
      modulating mitogen-activated protein kinase signaling. EphA3 knockdown or
      depletion of EphA3-positive tumor cells reduced tumorigenic potential to a degree
      comparable to treatment with a therapeutic radiolabelled EphA3-specific
      monoclonal antibody. These results identify EphA3 as a functional, targetable
      receptor in GBM.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Day, Bryan W
AU  - Day BW
AD  - Brain Cancer Research Unit and Leukaemia Foundation Research Unit, Queensland
      Institute of Medical Research, Brisbane 4006, Australia. bryan.day@qimr.edu.au
FAU - Stringer, Brett W
AU  - Stringer BW
FAU - Al-Ejeh, Fares
AU  - Al-Ejeh F
FAU - Ting, Michael J
AU  - Ting MJ
FAU - Wilson, John
AU  - Wilson J
FAU - Ensbey, Kathleen S
AU  - Ensbey KS
FAU - Jamieson, Paul R
AU  - Jamieson PR
FAU - Bruce, Zara C
AU  - Bruce ZC
FAU - Lim, Yi Chieh
AU  - Lim YC
FAU - Offenhauser, Carolin
AU  - Offenhauser C
FAU - Charmsaz, Sara
AU  - Charmsaz S
FAU - Cooper, Leanne T
AU  - Cooper LT
FAU - Ellacott, Jennifer K
AU  - Ellacott JK
FAU - Harding, Angus
AU  - Harding A
FAU - Leveque, Lucie
AU  - Leveque L
FAU - Inglis, Po
AU  - Inglis P
FAU - Allan, Suzanne
AU  - Allan S
FAU - Walker, David G
AU  - Walker DG
FAU - Lackmann, Martin
AU  - Lackmann M
FAU - Osborne, Geoffrey
AU  - Osborne G
FAU - Khanna, Kum Kum
AU  - Khanna KK
FAU - Reynolds, Brent A
AU  - Reynolds BA
FAU - Lickliter, Jason D
AU  - Lickliter JD
FAU - Boyd, Andrew W
AU  - Boyd AW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (RNA, Small Interfering)
RN  - EC 2.7.10.1 (EPHA3 protein, human)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
SB  - IM
CIN - Cancer Cell. 2013 Feb 11;23(2):135-7. PMID: 23410969
MH  - Animals
MH  - Antibodies, Monoclonal/pharmacology
MH  - Apoptosis
MH  - Blotting, Western
MH  - Brain Neoplasms/genetics/pathology/*prevention & control
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Flow Cytometry
MH  - Fluorescent Antibody Technique
MH  - Glioblastoma/genetics/pathology/*prevention & control
MH  - Humans
MH  - Immunoprecipitation
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Mitogen-Activated Protein Kinases/*metabolism
MH  - Neoplastic Stem Cells/*pathology
MH  - RNA, Small Interfering/genetics
MH  - Receptor Protein-Tyrosine Kinases/antagonists & inhibitors/genetics/*metabolism
MH  - Tumor Cells, Cultured
EDAT- 2013/02/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/16 06:00
PHST- 2011/08/05 [received]
PHST- 2012/03/21 [revised]
PHST- 2013/01/14 [accepted]
AID - S1535-6108(13)00032-9 [pii]
AID - 10.1016/j.ccr.2013.01.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.

PMID- 23410975
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20141116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation
      state impacts tumor characteristics.
PG  - 215-27
LID - 10.1016/j.ccr.2012.12.019 [doi]
LID - S1535-6108(13)00002-0 [pii]
AB  - Clear cell sarcoma (CCS) of tendons and aponeuroses is a deadly soft-tissue
      malignancy resembling melanoma, with a predilection for young adults. EWS-ATF1,
      the fusion product of a balanced chromosomal translocation between chromosomes 22
      and 12, is considered the definitional feature of the tumor. Conditional
      expression of the EWS-ATF1 human cDNA in the mouse generates CCS-like tumors with
      100% penetrance. Tumors, developed through varied means of initiating expression 
      of the fusion oncogene, model human CCS morphologically, immunohistochemically,
      and by genome-wide expression profiling. We also demonstrate that although fusion
      oncogene expression in later stages of differentiation can transform mesenchymal 
      progenitor cells and generate tumors resembling CCS generally, expression in
      cells retaining stem cell markers permits the full melanoma-related phenotype.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Straessler, Krystal M
AU  - Straessler KM
AD  - Department of Human Genetics, University of Utah School of Medicine, Salt Lake
      City, UT 84112, USA.
FAU - Jones, Kevin B
AU  - Jones KB
FAU - Hu, Hao
AU  - Hu H
FAU - Jin, Huifeng
AU  - Jin H
FAU - van de Rijn, Matt
AU  - van de Rijn M
FAU - Capecchi, Mario R
AU  - Capecchi MR
LA  - eng
SI  - GEO/GSE41293
SI  - GEO/GSE43045
GR  - K08 CA138764/CA/NCI NIH HHS/United States
GR  - K08CA138764K08/CA/NCI NIH HHS/United States
GR  - P30CA042014/CA/NCI NIH HHS/United States
GR  - R01 CA112270/CA/NCI NIH HHS/United States
GR  - R01 GM021168/GM/NIGMS NIH HHS/United States
GR  - R37 GM021168/GM/NIGMS NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (EWS-ATF1 fusion protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Markers, Biological)
SB  - IM
MH  - Animals
MH  - Blotting, Western
MH  - *Cell Differentiation
MH  - Cell Lineage/genetics
MH  - *Disease Models, Animal
MH  - Gene Expression Profiling
MH  - Humans
MH  - Male
MH  - Mesenchymal Stromal Cells/pathology
MH  - Mice
MH  - Oligonucleotide Array Sequence Analysis
MH  - Oncogene Proteins, Fusion/*genetics
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sarcoma, Clear Cell/genetics/*pathology
MH  - Soft Tissue Neoplasms/genetics/*pathology
MH  - Transcription Factors/*genetics
MH  - Tumor Markers, Biological/*genetics/metabolism
PMC - PMC3640275
MID - NIHMS459029
OID - NLM: NIHMS459029
OID - NLM: PMC3640275
EDAT- 2013/02/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/16 06:00
PHST- 2012/09/20 [received]
PHST- 2012/11/13 [revised]
PHST- 2012/12/26 [accepted]
AID - S1535-6108(13)00002-0 [pii]
AID - 10.1016/j.ccr.2012.12.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):215-27. doi: 10.1016/j.ccr.2012.12.019.

PMID- 23410974
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20150325
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Growth factor independence 1 antagonizes a p53-induced DNA damage response
      pathway in lymphoblastic leukemia.
PG  - 200-14
LID - 10.1016/j.ccr.2013.01.011 [doi]
LID - S1535-6108(13)00036-6 [pii]
AB  - Most patients with acute lymphoblastic leukemia (ALL) fail current treatments
      highlighting the need for better therapies. Because oncogenic signaling activates
      a p53-dependent DNA damage response and apoptosis, leukemic cells must devise
      appropriate countermeasures. We show here that growth factor independence 1
      (Gfi1) can serve such a function because Gfi1 ablation exacerbates p53 responses 
      and lowers the threshold for p53-induced cell death. Specifically, Gfi1 restricts
      p53 activity and expression of proapoptotic p53 targets such as Bax, Noxa
      (Pmaip1), and Puma (Bbc3). Subsequently, Gfi1 ablation cures mice from leukemia
      and limits the expansion of primary human T-ALL xenografts in mice. This suggests
      that targeting Gfi1 could improve the prognosis of patients with T-ALL or other
      lymphoid leukemias.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Khandanpour, Cyrus
AU  - Khandanpour C
AD  - Institut de recherches cliniques de Montreal (IRCM), 110 Avenue des Pins Ouest,
      Montreal, Quebec H2W 1R7, Canada.
FAU - Phelan, James D
AU  - Phelan JD
FAU - Vassen, Lothar
AU  - Vassen L
FAU - Schutte, Judith
AU  - Schutte J
FAU - Chen, Riyan
AU  - Chen R
FAU - Horman, Shane R
AU  - Horman SR
FAU - Gaudreau, Marie-Claude
AU  - Gaudreau MC
FAU - Krongold, Joseph
AU  - Krongold J
FAU - Zhu, Jinfang
AU  - Zhu J
FAU - Paul, William E
AU  - Paul WE
FAU - Duhrsen, Ulrich
AU  - Duhrsen U
FAU - Gottgens, Bertie
AU  - Gottgens B
FAU - Grimes, H Leighton
AU  - Grimes HL
FAU - Moroy, Tarik
AU  - Moroy T
LA  - eng
SI  - GEO/GSE32910
GR  - 079249/Wellcome Trust/United Kingdom
GR  - 100140/Wellcome Trust/United Kingdom
GR  - CA105152/CA/NCI NIH HHS/United States
GR  - CA159845/CA/NCI NIH HHS/United States
GR  - MOP-111011/Canadian Institutes of Health Research/Canada
GR  - MOP-84238/Canadian Institutes of Health Research/Canada
GR  - P30 DK090971/DK/NIDDK NIH HHS/United States
GR  - R01 CA105152/CA/NCI NIH HHS/United States
GR  - R01 CA159845/CA/NCI NIH HHS/United States
GR  - T32-CA117846/CA/NCI NIH HHS/United States
GR  - ZIA AI001169-01/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Gfi1 protein, mouse)
RN  - 0 (NOTCH1 protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Receptor, Notch1)
RN  - 0 (Transcription Factors)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Animals
MH  - *Apoptosis
MH  - DNA Damage/*genetics
MH  - DNA-Binding Proteins/*physiology
MH  - Humans
MH  - Lymphoma, B-Cell/genetics/mortality/*pathology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - Mutation/genetics
MH  - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics/mortality/*pathology
MH  - Proto-Oncogene Proteins c-bcl-2/metabolism
MH  - Receptor, Notch1/genetics
MH  - Transcription Factors/*physiology
MH  - Tumor Suppressor Protein p53/*physiology
MH  - Xenograft Model Antitumor Assays
PMC - PMC3597385
MID - NIHMS438414
OID - NLM: NIHMS438414
OID - NLM: PMC3597385
EDAT- 2013/02/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/16 06:00
PHST- 2011/12/22 [received]
PHST- 2012/09/11 [revised]
PHST- 2013/01/18 [accepted]
AID - S1535-6108(13)00036-6 [pii]
AID - 10.1016/j.ccr.2013.01.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):200-14. doi: 10.1016/j.ccr.2013.01.011.

PMID- 23410973
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20150224
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Integrated analyses identify a master microRNA regulatory network for the
      mesenchymal subtype in serous ovarian cancer.
PG  - 186-99
LID - 10.1016/j.ccr.2012.12.020 [doi]
LID - S1535-6108(13)00003-2 [pii]
AB  - Integrated genomic analyses revealed a miRNA-regulatory network that further
      defined a robust integrated mesenchymal subtype associated with poor overall
      survival in 459 cases of serous ovarian cancer (OvCa) from The Cancer Genome
      Atlas and 560 cases from independent cohorts. Eight key miRNAs, including
      miR-506, miR-141, and miR-200a, were predicted to regulate 89% of the targets in 
      this network. Follow-up functional experiments illustrate that miR-506 augmented 
      E-cadherin expression, inhibited cell migration and invasion, and prevented
      TGFbeta-induced epithelial-mesenchymal transition by targeting SNAI2, a
      transcriptional repressor of E-cadherin. In human OvCa, miR-506 expression was
      correlated with decreased SNAI2 and VIM, elevated E-cadherin, and beneficial
      prognosis. Nanoparticle delivery of miR-506 in orthotopic OvCa mouse models led
      to E-cadherin induction and reduced tumor growth.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Yang, Da
AU  - Yang D
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center,
      Houston, TX 77030, USA.
FAU - Sun, Yan
AU  - Sun Y
FAU - Hu, Limei
AU  - Hu L
FAU - Zheng, Hong
AU  - Zheng H
FAU - Ji, Ping
AU  - Ji P
FAU - Pecot, Chad V
AU  - Pecot CV
FAU - Zhao, Yanrui
AU  - Zhao Y
FAU - Reynolds, Sheila
AU  - Reynolds S
FAU - Cheng, Hanyin
AU  - Cheng H
FAU - Rupaimoole, Rajesha
AU  - Rupaimoole R
FAU - Cogdell, David
AU  - Cogdell D
FAU - Nykter, Matti
AU  - Nykter M
FAU - Broaddus, Russell
AU  - Broaddus R
FAU - Rodriguez-Aguayo, Cristian
AU  - Rodriguez-Aguayo C
FAU - Lopez-Berestein, Gabriel
AU  - Lopez-Berestein G
FAU - Liu, Jinsong
AU  - Liu J
FAU - Shmulevich, Ilya
AU  - Shmulevich I
FAU - Sood, Anil K
AU  - Sood AK
FAU - Chen, Kexin
AU  - Chen K
FAU - Zhang, Wei
AU  - Zhang W
LA  - eng
GR  - CA016672/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - P50 CA083639/CA/NCI NIH HHS/United States
GR  - P50 CA098258/CA/NCI NIH HHS/United States
GR  - R01 CA109298/CA/NCI NIH HHS/United States
GR  - T32 CA009666/CA/NCI NIH HHS/United States
GR  - U24 CA143835/CA/NCI NIH HHS/United States
GR  - U24CA143835/CA/NCI NIH HHS/United States
GR  - U54 CA151668/CA/NCI NIH HHS/United States
GR  - U54 CA151668/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cadherins)
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Messenger)
RN  - 0 (Transcription Factors)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Tumor Markers, Biological)
RN  - 0 (Vimentin)
RN  - 0 (snail family transcription factors)
SB  - IM
EIN - Cancer Cell. 2013 May 13;23(5):705
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Blotting, Western
MH  - Cadherins/genetics/metabolism
MH  - Cell Movement
MH  - Cell Proliferation/drug effects
MH  - Cystadenocarcinoma, Serous/*genetics/mortality/pathology
MH  - Epithelial-Mesenchymal Transition/*genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Mesoderm/metabolism/*pathology
MH  - Mice
MH  - Mice, Nude
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Ovarian Neoplasms/*genetics/mortality/pathology
MH  - Prognosis
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Survival Rate
MH  - Transcription Factors/genetics/metabolism
MH  - Transforming Growth Factor beta/genetics/metabolism
MH  - Tumor Cells, Cultured
MH  - Tumor Markers, Biological/*genetics
MH  - Vimentin/genetics/metabolism
PMC - PMC3603369
MID - NIHMS432872
OID - NLM: NIHMS432872
OID - NLM: PMC3603369
EDAT- 2013/02/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/16 06:00
PHST- 2011/01/23 [received]
PHST- 2011/11/08 [revised]
PHST- 2012/12/28 [accepted]
AID - S1535-6108(13)00003-2 [pii]
AID - 10.1016/j.ccr.2012.12.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):186-99. doi: 10.1016/j.ccr.2012.12.020.

PMID- 23410972
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20140303
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Integrative genomic analyses reveal an androgen-driven somatic alteration
      landscape in early-onset prostate cancer.
PG  - 159-70
LID - 10.1016/j.ccr.2013.01.002 [doi]
LID - S1535-6108(13)00004-4 [pii]
AB  - Early-onset prostate cancer (EO-PCA) represents the earliest clinical
      manifestation of prostate cancer. To compare the genomic alteration landscapes of
      EO-PCA with "classical" (elderly-onset) PCA, we performed deep sequencing-based
      genomics analyses in 11 tumors diagnosed at young age, and pursued comparative
      assessments with seven elderly-onset PCA genomes. Remarkable age-related
      differences in structural rearrangement (SR) formation became evident, suggesting
      distinct disease pathomechanisms. Whereas EO-PCAs harbored a prevalence of
      balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions
      including TMPRSS2:ERG, elderly-onset PCAs displayed primarily
      non-androgen-associated SRs. Data from a validation cohort of > 10,000 patients
      showed age-dependent androgen receptor levels and a prevalence of SRs affecting
      androgen-regulated genes, further substantiating the activity of a characteristic
      "androgen-type" pathomechanism in EO-PCA.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Weischenfeldt, Joachim
AU  - Weischenfeldt J
AD  - Genome Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstr.
      1, 69117 Heidelberg, Germany.
FAU - Simon, Ronald
AU  - Simon R
FAU - Feuerbach, Lars
AU  - Feuerbach L
FAU - Schlangen, Karin
AU  - Schlangen K
FAU - Weichenhan, Dieter
AU  - Weichenhan D
FAU - Minner, Sarah
AU  - Minner S
FAU - Wuttig, Daniela
AU  - Wuttig D
FAU - Warnatz, Hans-Jorg
AU  - Warnatz HJ
FAU - Stehr, Henning
AU  - Stehr H
FAU - Rausch, Tobias
AU  - Rausch T
FAU - Jager, Natalie
AU  - Jager N
FAU - Gu, Lei
AU  - Gu L
FAU - Bogatyrova, Olga
AU  - Bogatyrova O
FAU - Stutz, Adrian M
AU  - Stutz AM
FAU - Claus, Rainer
AU  - Claus R
FAU - Eils, Jurgen
AU  - Eils J
FAU - Eils, Roland
AU  - Eils R
FAU - Gerhauser, Clarissa
AU  - Gerhauser C
FAU - Huang, Po-Hsien
AU  - Huang PH
FAU - Hutter, Barbara
AU  - Hutter B
FAU - Kabbe, Rolf
AU  - Kabbe R
FAU - Lawerenz, Christian
AU  - Lawerenz C
FAU - Radomski, Sylwester
AU  - Radomski S
FAU - Bartholomae, Cynthia C
AU  - Bartholomae CC
FAU - Falth, Maria
AU  - Falth M
FAU - Gade, Stephan
AU  - Gade S
FAU - Schmidt, Manfred
AU  - Schmidt M
FAU - Amschler, Nina
AU  - Amschler N
FAU - Hass, Thomas
AU  - Hass T
FAU - Galal, Rami
AU  - Galal R
FAU - Gjoni, Jovisa
AU  - Gjoni J
FAU - Kuner, Ruprecht
AU  - Kuner R
FAU - Baer, Constance
AU  - Baer C
FAU - Masser, Sawinee
AU  - Masser S
FAU - von Kalle, Christof
AU  - von Kalle C
FAU - Zichner, Thomas
AU  - Zichner T
FAU - Benes, Vladimir
AU  - Benes V
FAU - Raeder, Benjamin
AU  - Raeder B
FAU - Mader, Malte
AU  - Mader M
FAU - Amstislavskiy, Vyacheslav
AU  - Amstislavskiy V
FAU - Avci, Meryem
AU  - Avci M
FAU - Lehrach, Hans
AU  - Lehrach H
FAU - Parkhomchuk, Dmitri
AU  - Parkhomchuk D
FAU - Sultan, Marc
AU  - Sultan M
FAU - Burkhardt, Lia
AU  - Burkhardt L
FAU - Graefen, Markus
AU  - Graefen M
FAU - Huland, Hartwig
AU  - Huland H
FAU - Kluth, Martina
AU  - Kluth M
FAU - Krohn, Antje
AU  - Krohn A
FAU - Sirma, Huseyin
AU  - Sirma H
FAU - Stumm, Laura
AU  - Stumm L
FAU - Steurer, Stefan
AU  - Steurer S
FAU - Grupp, Katharina
AU  - Grupp K
FAU - Sultmann, Holger
AU  - Sultmann H
FAU - Sauter, Guido
AU  - Sauter G
FAU - Plass, Christoph
AU  - Plass C
FAU - Brors, Benedikt
AU  - Brors B
FAU - Yaspo, Marie-Laure
AU  - Yaspo ML
FAU - Korbel, Jan O
AU  - Korbel JO
FAU - Schlomm, Thorsten
AU  - Schlomm T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AR protein, human)
RN  - 0 (ERG protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (Receptors, Androgen)
RN  - 0 (Trans-Activators)
RN  - EC 3.4.21.- (Serine Endopeptidases)
RN  - EC 3.4.21.- (TMPRSS2 protein, human)
SB  - IM
CIN - Urol Oncol. 2014 Feb;32(2):212. PMID: 24445294
CIN - Aktuelle Urol. 2013 Mar;44(2):99-100. PMID: 23592286
CIN - Cancer Cell. 2013 Feb 11;23(2):133-5. PMID: 23410968
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Computational Biology
MH  - *Gene Rearrangement
MH  - *Genomics
MH  - High-Throughput Nucleotide Sequencing
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/*genetics
MH  - Prostatic Neoplasms/*genetics
MH  - Receptors, Androgen/*genetics
MH  - Serine Endopeptidases/*genetics
MH  - Trans-Activators/*genetics
EDAT- 2013/02/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/16 06:00
PHST- 2012/05/10 [received]
PHST- 2012/08/16 [revised]
PHST- 2013/01/03 [accepted]
AID - S1535-6108(13)00004-4 [pii]
AID - 10.1016/j.ccr.2013.01.002 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):159-70. doi: 10.1016/j.ccr.2013.01.002.

PMID- 23410971
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20130701
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - ABT-199: taking dead aim at BCL-2.
PG  - 139-41
LID - 10.1016/j.ccr.2013.01.018 [doi]
LID - S1535-6108(13)00039-1 [pii]
AB  - ABT-199 is a new selective small molecule inhibitor of BCL-2 that appears to
      spare platelets while achieving potent antitumor activity. Assays that can
      predict the efficacy of ABT-199 in individual tumors will be critical in
      determining how best to incorporate this promising agent into the armamentarium
      of cancer therapies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Davids, Matthew S
AU  - Davids MS
AD  - Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline
      Avenue, Boston, MA 02215, USA.
FAU - Letai, Anthony
AU  - Letai A
LA  - eng
GR  - R01 CA129974/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
PMC - PMC3693952
MID - NIHMS481683
OID - NLM: NIHMS481683
OID - NLM: PMC3693952
EDAT- 2013/02/16 06:00
MHDA- 2013/02/16 06:01
CRDT- 2013/02/16 06:00
AID - S1535-6108(13)00039-1 [pii]
AID - 10.1016/j.ccr.2013.01.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):139-41. doi: 10.1016/j.ccr.2013.01.018.

PMID- 23410970
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20140415
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Breaking news on fragile sites in cancer.
PG  - 137-9
LID - 10.1016/j.ccr.2013.01.017 [doi]
LID - S1535-6108(13)00038-X [pii]
AB  - Chromosome rearrangements in B lymphocytes can be initiated by AID-associated
      double strand breaks (DSBs), with others arising by unclear mechanisms. A recent 
      study by Barlow and colleagues in Cell reports on genomic regions, termed early
      replicating fragile sites, that may explain many AID-independent DSBs and creates
      a compelling link between replication stress, transcription, and chromosome
      rearrangements.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Glover, Thomas W
AU  - Glover TW
AD  - Department of Human Genetics, University of Michigan, Ann Arbor, MI 48109, USA.
      glover@umich.edu
FAU - Wilson, Thomas E
AU  - Wilson TE
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cell. 2013 Jan 31;152(3):620-32. PMID: 23352430
EDAT- 2013/02/16 06:00
MHDA- 2013/02/16 06:01
CRDT- 2013/02/16 06:00
AID - S1535-6108(13)00038-X [pii]
AID - 10.1016/j.ccr.2013.01.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):137-9. doi: 10.1016/j.ccr.2013.01.017.

PMID- 23410969
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20130408
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Growth factor receptors define cancer hierarchies.
PG  - 135-7
LID - 10.1016/j.ccr.2013.01.020 [doi]
LID - S1535-6108(13)00041-X [pii]
AB  - Normal and neoplastic tissues display cellular hierarchies that integrate
      extracellular cues to maintain tissue function through bidirectional signals
      mediated via cell surface proteins. Two papers in Cancer Cell, one in this issue 
      (Day and colleagues) and one in a recent issue (Binda and colleagues), describe
      how Eph receptor tyrosine kinases critically define and regulate the growth of
      cancer stem cells.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Venere, Monica
AU  - Venere M
AD  - Department of Stem Cell Biology and Regenerative Medicine, Lerner Research
      Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
FAU - Lathia, Justin D
AU  - Lathia JD
FAU - Rich, Jeremy N
AU  - Rich JN
LA  - eng
GR  - R00 CA157948/CA/NCI NIH HHS/United States
GR  - R01 CA129958/CA/NCI NIH HHS/United States
GR  - R01 CA154130/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Feb 11;23(2):238-48. PMID: 23410976
CON - Cancer Cell. 2012 Dec 11;22(6):765-80. PMID: 23238013
PMC - PMC3616317
MID - NIHMS454122
OID - NLM: NIHMS454122
OID - NLM: PMC3616317
EDAT- 2013/02/16 06:00
MHDA- 2013/02/16 06:01
CRDT- 2013/02/16 06:00
AID - S1535-6108(13)00041-X [pii]
AID - 10.1016/j.ccr.2013.01.020 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):135-7. doi: 10.1016/j.ccr.2013.01.020.

PMID- 23410968
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20140212
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Molecular archeology: unearthing androgen-induced structural rearrangements in
      prostate cancer genomes.
PG  - 133-5
LID - 10.1016/j.ccr.2013.01.019 [doi]
LID - S1535-6108(13)00040-8 [pii]
AB  - In this issue of Cancer Cell, Weischenfeldt and colleagues report on the whole
      genome sequencing of 11 early-onset prostate cancers. Compared to elderly onset
      prostate cancer, these tumors demonstrate enrichment for androgen-driven
      structural rearrangements involving ETS family genes. This study confirms
      observations that prostate cancer manifests discrete genomic subclasses.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Demichelis, Francesca
AU  - Demichelis F
AD  - Centre for Integrative Biology, University of Trento, Povo, Trento, 38123, Italy.
FAU - Garraway, Levi A
AU  - Garraway LA
FAU - Rubin, Mark A
AU  - Rubin MA
LA  - eng
GR  - R01 CA125612/CA/NCI NIH HHS/United States
GR  - U01CA111275/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Feb 11;23(2):159-70. PMID: 23410972
PMC - PMC3630373
MID - NIHMS458694
OID - NLM: NIHMS458694
OID - NLM: PMC3630373
EDAT- 2013/02/16 06:00
MHDA- 2013/02/16 06:01
CRDT- 2013/02/16 06:00
AID - S1535-6108(13)00040-8 [pii]
AID - 10.1016/j.ccr.2013.01.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):133-5. doi: 10.1016/j.ccr.2013.01.019.

PMID- 23410967
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20140224
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - The LKB1-AMPK pathway-friend or foe in cancer?
PG  - 131-2
LID - 10.1016/j.ccr.2013.01.009 [doi]
LID - S1535-6108(13)00035-4 [pii]
AB  - Use of the biguanide metformin, an AMPK activator, is associated with a reduced
      incidence of cancer in diabetics, but it has been unclear whether this requires
      AMPK. In this issue of Cancer Cell, Shackelford and colleagues show,
      paradoxically, that biguanides are more effective in the treatment of mouse
      tumors that lack a functional LKB1-AMPK pathway.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Hardie, D Grahame
AU  - Hardie DG
AD  - Division of Cell Signalling and Immunology, College of Life Sciences, University 
      of Dundee, Dundee DD1 5EH, Scotland, UK. d.g.hardie@dundee.ac.uk
LA  - eng
GR  - 097726/Wellcome Trust/United Kingdom
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Feb 11;23(2):143-58. PMID: 23352126
EDAT- 2013/02/16 06:00
MHDA- 2013/02/16 06:01
CRDT- 2013/02/16 06:00
AID - S1535-6108(13)00035-4 [pii]
AID - 10.1016/j.ccr.2013.01.009 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):131-2. doi: 10.1016/j.ccr.2013.01.009.

PMID- 23375636
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20150116
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Endothelial cells promote the colorectal cancer stem cell phenotype through a
      soluble form of Jagged-1.
PG  - 171-85
LID - 10.1016/j.ccr.2012.12.021 [doi]
LID - S1535-6108(13)00031-7 [pii]
AB  - We report a paracrine effect whereby endothelial cells (ECs) promote the cancer
      stem cell (CSC) phenotype of human colorectal cancer (CRC) cells. We showed that,
      without direct cell-cell contact, ECs secrete factors that promoted the CSC
      phenotype in CRC cells via Notch activation. In human CRC specimens, CD133 and
      Notch intracellular domain-positive CRC cells colocalized in perivascular
      regions. An EC-derived, soluble form of Jagged-1, via ADAM17 proteolytic
      activity, led to Notch activation in CRC cells in a paracrine manner; these
      effects were blocked by immunodepletion of Jagged-1 in EC-conditioned medium or
      blockade of ADAM17 activity. Collectively, ECs play an active role in promoting
      Notch signaling and the CSC phenotype by secreting soluble Jagged-1.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Lu, Jia
AU  - Lu J
AD  - Department of Cancer Biology, The University of Texas M.D. Anderson Cancer
      Center, Houston, TX 77030, USA.
FAU - Ye, Xiangcang
AU  - Ye X
FAU - Fan, Fan
AU  - Fan F
FAU - Xia, Ling
AU  - Xia L
FAU - Bhattacharya, Rajat
AU  - Bhattacharya R
FAU - Bellister, Seth
AU  - Bellister S
FAU - Tozzi, Federico
AU  - Tozzi F
FAU - Sceusi, Eric
AU  - Sceusi E
FAU - Zhou, Yunfei
AU  - Zhou Y
FAU - Tachibana, Isamu
AU  - Tachibana I
FAU - Maru, Dipen M
AU  - Maru DM
FAU - Hawke, David H
AU  - Hawke DH
FAU - Rak, Janusz
AU  - Rak J
FAU - Mani, Sendurai A
AU  - Mani SA
FAU - Zweidler-McKay, Patrick
AU  - Zweidler-McKay P
FAU - Ellis, Lee M
AU  - Ellis LM
LA  - eng
GR  - CA016672/CA/NCI NIH HHS/United States
GR  - CA100879/CA/NCI NIH HHS/United States
GR  - P30 CA016672/CA/NCI NIH HHS/United States
GR  - R01 CA157880/CA/NCI NIH HHS/United States
GR  - R01CA157880/CA/NCI NIH HHS/United States
GR  - T32 CA009599/CA/NCI NIH HHS/United States
GR  - T32CA009599/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, U.S. Gov't, Non-P.H.S.
DEP - 20130131
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biological Markers)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (RNA, Small Interfering)
RN  - 0 (Receptors, Notch)
RN  - 134324-36-0 (Serrate proteins)
RN  - EC 3.4.24.- (ADAM Proteins)
RN  - EC 3.4.24.- (tumor necrosis factor-alpha convertase)
SB  - IM
MH  - ADAM Proteins/antagonists & inhibitors/genetics/metabolism
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Biological Markers/metabolism
MH  - Calcium-Binding Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Cell Communication
MH  - Colorectal Neoplasms/genetics/metabolism/*pathology
MH  - Culture Media, Conditioned/pharmacology
MH  - Drug Resistance, Neoplasm
MH  - Endothelial Cells/metabolism/*pathology
MH  - Humans
MH  - Immunoblotting
MH  - Immunoprecipitation
MH  - Intercellular Signaling Peptides and Proteins/genetics/*metabolism
MH  - Liver Neoplasms/genetics/metabolism/*secondary
MH  - Membrane Proteins/antagonists & inhibitors/genetics/*metabolism
MH  - Mice
MH  - Mice, Nude
MH  - Neoplastic Stem Cells/metabolism/*pathology
MH  - Peptide Fragments/pharmacology
MH  - Phenotype
MH  - RNA, Small Interfering/genetics
MH  - Receptors, Notch/*metabolism
MH  - Signal Transduction
MH  - Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC3574187
MID - NIHMS435041
OID - NLM: NIHMS435041
OID - NLM: PMC3574187
EDAT- 2013/02/05 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/02/05 06:00
PHST- 2011/09/16 [received]
PHST- 2012/03/12 [revised]
PHST- 2012/12/21 [accepted]
PHST- 2013/01/31 [aheadofprint]
AID - S1535-6108(13)00031-7 [pii]
AID - 10.1016/j.ccr.2012.12.021 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):171-85. doi: 10.1016/j.ccr.2012.12.021. Epub 2013 
      Jan 31.

PMID- 23352416
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20150325
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - Englerin A stimulates PKCtheta to inhibit insulin signaling and to simultaneously
      activate HSF1: pharmacologically induced synthetic lethality.
PG  - 228-37
LID - 10.1016/j.ccr.2012.12.007 [doi]
LID - S1535-6108(12)00517-X [pii]
AB  - The natural product englerin A (EA) binds to and activates protein kinase C-theta
      (PKCtheta). EA-dependent activation of PKCtheta induces an insulin-resistant
      phenotype, limiting the access of tumor cells to glucose. At the same time, EA
      causes PKCtheta-mediated phosphorylation and activation of the transcription
      factor heat shock factor 1, an inducer of glucose dependence. By promoting
      glucose addiction, while simultaneously starving cells of glucose, EA proves to
      be synthetically lethal to highly glycolytic tumors.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Sourbier, Carole
AU  - Sourbier C
AD  - Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, 
      National Institutes of Health, Bethesda, MD 20892, USA.
FAU - Scroggins, Bradley T
AU  - Scroggins BT
FAU - Ratnayake, Ranjala
AU  - Ratnayake R
FAU - Prince, Thomas L
AU  - Prince TL
FAU - Lee, Sunmin
AU  - Lee S
FAU - Lee, Min-Jung
AU  - Lee MJ
FAU - Nagy, Peter Literati
AU  - Nagy PL
FAU - Lee, Young H
AU  - Lee YH
FAU - Trepel, Jane B
AU  - Trepel JB
FAU - Beutler, John A
AU  - Beutler JA
FAU - Linehan, W Marston
AU  - Linehan WM
FAU - Neckers, Len
AU  - Neckers L
LA  - eng
GR  - Z01 BC010683-03/Intramural NIH HHS/United States
GR  - Z01 SC010074-12/Intramural NIH HHS/United States
GR  - Z01 SC010074-13/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
DEP - 20130123
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Hsf1 protein, mouse)
RN  - 0 (Insulin)
RN  - 0 (Isoenzymes)
RN  - 0 (Sesquiterpenes, Guaiane)
RN  - 0 (Transcription Factors)
RN  - 0 (englerin A)
RN  - EC 2.7.1.- (Prkcq protein, mouse)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Blotting, Western
MH  - Cell Proliferation
MH  - DNA-Binding Proteins/*metabolism
MH  - Glucose/*metabolism
MH  - Humans
MH  - Immunoprecipitation
MH  - Insulin/chemistry/*metabolism
MH  - *Insulin Resistance
MH  - Isoenzymes/*metabolism
MH  - Kidney Neoplasms/*drug therapy/metabolism/pathology
MH  - Mice
MH  - Phosphorylation/drug effects
MH  - Protein Kinase C/*metabolism
MH  - Sesquiterpenes, Guaiane/*pharmacology
MH  - Signal Transduction/*drug effects
MH  - Transcription Factors/*metabolism
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC3574184
MID - NIHMS431577
OID - NLM: NIHMS431577
OID - NLM: PMC3574184
EDAT- 2013/01/29 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/01/29 06:00
PHST- 2012/06/04 [received]
PHST- 2012/10/19 [revised]
PHST- 2012/12/18 [accepted]
PHST- 2013/01/23 [aheadofprint]
AID - S1535-6108(12)00517-X [pii]
AID - 10.1016/j.ccr.2012.12.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):228-37. doi: 10.1016/j.ccr.2012.12.007. Epub 2013 
      Jan 23.

PMID- 23352126
OWN - NLM
STAT- MEDLINE
DA  - 20130215
DCOM- 20130404
LR  - 20141103
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 2
DP  - 2013 Feb 11
TI  - LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to 
      the metabolism drug phenformin.
PG  - 143-58
LID - 10.1016/j.ccr.2012.12.008 [doi]
LID - S1535-6108(12)00518-1 [pii]
AB  - The LKB1 (also called STK11) tumor suppressor is mutationally inactivated in
      approximately 20% of non-small cell lung cancers (NSCLC). LKB1 is the major
      upstream kinase activating the energy-sensing kinase AMPK, making LKB1-deficient 
      cells unable to appropriately sense metabolic stress. We tested the therapeutic
      potential of metabolic drugs in NSCLC and identified phenformin, a mitochondrial 
      inhibitor and analog of the diabetes therapeutic metformin, as selectively
      inducing apoptosis in LKB1-deficient NSCLC cells. Therapeutic trials in
      Kras-dependent mouse models of NSCLC revealed that tumors with Kras and Lkb1
      mutations, but not those with Kras and p53 mutations, showed selective response
      to phenformin as a single agent, resulting in prolonged survival. This study
      suggests phenformin as a cancer metabolism-based therapeutic to selectively
      target LKB1-deficient tumors.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Shackelford, David B
AU  - Shackelford DB
AD  - Molecular and Cell Biology Laboratory, Dulbecco Center for Cancer Research, The
      Salk Institute for Biological Studies, La Jolla, CA 92037, USA.
      dshackelford@mednet.ucla.edu
FAU - Abt, Evan
AU  - Abt E
FAU - Gerken, Laurie
AU  - Gerken L
FAU - Vasquez, Debbie S
AU  - Vasquez DS
FAU - Seki, Atsuko
AU  - Seki A
FAU - Leblanc, Mathias
AU  - Leblanc M
FAU - Wei, Liu
AU  - Wei L
FAU - Fishbein, Michael C
AU  - Fishbein MC
FAU - Czernin, Johannes
AU  - Czernin J
FAU - Mischel, Paul S
AU  - Mischel PS
FAU - Shaw, Reuben J
AU  - Shaw RJ
LA  - eng
GR  - KL2 TR000122/TR/NCATS NIH HHS/United States
GR  - KL2TR000122/TR/NCATS NIH HHS/United States
GR  - P01 CA120964/CA/NCI NIH HHS/United States
GR  - P01CA120964/CA/NCI NIH HHS/United States
GR  - P30 CA014195/CA/NCI NIH HHS/United States
GR  - P30 CA014195/CA/NCI NIH HHS/United States
GR  - R01 CA172229/CA/NCI NIH HHS/United States
GR  - R01 DK080425/DK/NIDDK NIH HHS/United States
GR  - R01 DK080425/DK/NIDDK NIH HHS/United States
GR  - S10RR026744/RR/NCRR NIH HHS/United States
GR  - T32 CA009370/CA/NCI NIH HHS/United States
GR  - T32 CA009370/CA/NCI NIH HHS/United States
GR  - UL1TR000124/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130124
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Eukaryotic Initiation Factor-2)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - DD5K7529CE (Phenformin)
RN  - EC 2.7.1.- (Stk11 protein, mouse)
RN  - EC 2.7.11.1 (AMP-Activated Protein Kinases)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
SB  - IM
CIN - Cancer Cell. 2013 Feb 11;23(2):131-2. PMID: 23410967
CIN - Cancer Discov. 2013 Mar;3(3):OF14. PMID: 23475884
MH  - AMP-Activated Protein Kinases/genetics/metabolism
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Blotting, Western
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/metabolism/pathology
MH  - Cell Proliferation/drug effects
MH  - Cells, Cultured
MH  - Eukaryotic Initiation Factor-2/genetics/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Lung Neoplasms/*drug therapy/metabolism/pathology
MH  - Mice
MH  - Mice, Knockout
MH  - Mitochondria/drug effects/metabolism/pathology
MH  - Mutation/genetics
MH  - Phenformin/*therapeutic use
MH  - Protein-Serine-Threonine Kinases/antagonists & inhibitors/*physiology
MH  - Proto-Oncogene Proteins p21(ras)/physiology
MH  - RNA, Messenger/genetics
MH  - Real-Time Polymerase Chain Reaction
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Tumor Suppressor Protein p53/*physiology
PMC - PMC3579627
MID - NIHMS431762
OID - NLM: NIHMS431762
OID - NLM: PMC3579627
EDAT- 2013/01/29 06:00
MHDA- 2013/04/05 06:00
CRDT- 2013/01/29 06:00
PHST- 2011/05/16 [received]
PHST- 2012/10/07 [revised]
PHST- 2012/12/20 [accepted]
PHST- 2013/01/24 [aheadofprint]
AID - S1535-6108(12)00518-1 [pii]
AID - 10.1016/j.ccr.2012.12.008 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Feb 11;23(2):143-58. doi: 10.1016/j.ccr.2012.12.008. Epub 2013 
      Jan 24.

PMID- 23328482
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20141104
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is
      indispensable for the survival of chronic lymphocytic leukemia B cells in vivo.
PG  - 77-92
LID - 10.1016/j.ccr.2012.12.003 [doi]
LID - S1535-6108(12)00515-6 [pii]
AB  - Tumor cell survival critically depends on heterotypic communication with benign
      cells in the microenvironment. Here, we describe a survival signaling pathway
      activated in stromal cells by contact to B cells from patients with chronic
      lymphocytic leukemia (CLL). The expression of protein kinase C (PKC)-betaII and
      the subsequent activation of NF-kappaB in bone marrow stromal cells are
      prerequisites to support the survival of malignant B cells. PKC-beta knockout
      mice are insusceptible to CLL transplantations, underscoring the in vivo
      significance of the PKC-betaII-NF-kappaB signaling pathway in the tumor
      microenvironment. Upregulated stromal PKC-betaII in biopsies from patients with
      CLL, acute lymphoblastic leukemia, and mantle cell lymphoma suggests that this
      pathway may commonly be activated in a variety of hematological malignancies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Lutzny, Gloria
AU  - Lutzny G
AD  - Department of Hematology, Oncology, Technical University, 81675 Munich, Germany.
FAU - Kocher, Thomas
AU  - Kocher T
FAU - Schmidt-Supprian, Marc
AU  - Schmidt-Supprian M
FAU - Rudelius, Martina
AU  - Rudelius M
FAU - Klein-Hitpass, Ludger
AU  - Klein-Hitpass L
FAU - Finch, Andrew J
AU  - Finch AJ
FAU - Durig, Jan
AU  - Durig J
FAU - Wagner, Michaela
AU  - Wagner M
FAU - Haferlach, Claudia
AU  - Haferlach C
FAU - Kohlmann, Alexander
AU  - Kohlmann A
FAU - Schnittger, Susanne
AU  - Schnittger S
FAU - Seifert, Marc
AU  - Seifert M
FAU - Wanninger, Stefan
AU  - Wanninger S
FAU - Zaborsky, Nadja
AU  - Zaborsky N
FAU - Oostendorp, Robert
AU  - Oostendorp R
FAU - Ruland, Jurgen
AU  - Ruland J
FAU - Leitges, Michael
AU  - Leitges M
FAU - Kuhnt, Toni
AU  - Kuhnt T
FAU - Schafer, Yvonne
AU  - Schafer Y
FAU - Lampl, Benedikt
AU  - Lampl B
FAU - Peschel, Christian
AU  - Peschel C
FAU - Egle, Alexander
AU  - Egle A
FAU - Ringshausen, Ingo
AU  - Ringshausen I
LA  - eng
SI  - GEO/GSE36416
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Cytokines)
RN  - 0 (NF-kappa B)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 2.7.11.13 (Protein Kinase C beta)
SB  - IM
CIN - Nat Rev Cancer. 2013 Mar;13(3):145. PMID: 23363988
MH  - Animals
MH  - B-Lymphocytes/metabolism/*pathology
MH  - Cytokines/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/metabolism/*pathology
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Transgenic
MH  - NF-kappa B/*genetics/metabolism
MH  - Protein Kinase C/genetics/metabolism/*physiology
MH  - Protein Kinase C beta
MH  - Signal Transduction
MH  - Stromal Cells/metabolism
MH  - Tumor Microenvironment
PMC - PMC3546417
OID - NLM: PMC3546417
EDAT- 2013/01/19 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/01/19 06:00
PHST- 2012/02/23 [received]
PHST- 2012/09/03 [revised]
PHST- 2012/12/06 [accepted]
AID - S1535-6108(12)00515-6 [pii]
AID - 10.1016/j.ccr.2012.12.003 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):77-92. doi: 10.1016/j.ccr.2012.12.003.

PMID- 23328481
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20131121
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Suppression of miRNA-708 by polycomb group promotes metastases by calcium-induced
      cell migration.
PG  - 63-76
LID - 10.1016/j.ccr.2012.11.019 [doi]
LID - S1535-6108(12)00508-9 [pii]
AB  - The progression of cancer to metastatic disease is a major cause of death. We
      identified miR-708 being transcriptionally repressed by polycomb repressor
      complex 2-induced H3K27 trimethylation in metastatic breast cancer. miR-708
      targets the endoplasmic reticulum protein neuronatin to decrease intracellular
      calcium level, resulting in reduction of activation of ERK and FAK, decreased
      cell migration, and impaired metastases. Ectopic expression of neuronatin
      refractory to suppression by miR-708 rescued cell migration and metastasis
      defects. In patients with breast cancer, miR-708 expression was decreased in
      lymph node and distal metastases, suggesting a metastasis-suppressive role. Our
      findings uncover a mechanistic role for miR-708 in metastasis and provide a
      rationale for developing miR-708 as a therapeutic agent against metastatic breast
      cancer.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Ryu, Seongho
AU  - Ryu S
AD  - Department of Cardiothoracic Surgery, Weill Cornell Medical College of Cornell
      University, New York, NY 10065, USA.
FAU - McDonnell, Kevin
AU  - McDonnell K
FAU - Choi, Hyejin
AU  - Choi H
FAU - Gao, Dingcheng
AU  - Gao D
FAU - Hahn, Mary
AU  - Hahn M
FAU - Joshi, Natasha
AU  - Joshi N
FAU - Park, Sun-Mi
AU  - Park SM
FAU - Catena, Raul
AU  - Catena R
FAU - Do, Yoonkyung
AU  - Do Y
FAU - Brazin, Jacqueline
AU  - Brazin J
FAU - Vahdat, Linda T
AU  - Vahdat LT
FAU - Silver, Randi B
AU  - Silver RB
FAU - Mittal, Vivek
AU  - Mittal V
LA  - eng
SI  - GEO/GSE42313
GR  - U54CA143876/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (MIRN708 microRNA, human)
RN  - 0 (Membrane Proteins)
RN  - 0 (MicroRNAs)
RN  - 0 (NNAT protein, human)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Polycomb-Group Proteins)
RN  - EC 2.7.10.2 (Focal Adhesion Kinase 1)
RN  - EC 2.7.10.2 (PTK2 protein, human)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Animals
MH  - Breast Neoplasms/*genetics/pathology
MH  - Calcium/*metabolism
MH  - Cell Movement
MH  - Extracellular Signal-Regulated MAP Kinases/genetics/metabolism
MH  - Female
MH  - Focal Adhesion Kinase 1/genetics/metabolism
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/genetics/secondary
MH  - MAP Kinase Signaling System/genetics
MH  - Membrane Proteins/*genetics/metabolism/physiology
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Neoplasm Metastasis/*genetics
MH  - Nerve Tissue Proteins/*genetics/metabolism/physiology
MH  - Polycomb-Group Proteins/*physiology
EDAT- 2013/01/19 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/01/19 06:00
PHST- 2011/09/27 [received]
PHST- 2012/09/13 [revised]
PHST- 2012/11/30 [accepted]
AID - S1535-6108(12)00508-9 [pii]
AID - 10.1016/j.ccr.2012.11.019 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):63-76. doi: 10.1016/j.ccr.2012.11.019.

PMID- 23328480
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20150125
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - NEK2 induces drug resistance mainly through activation of efflux drug pumps and
      is associated with poor prognosis in myeloma and other cancers.
PG  - 48-62
LID - 10.1016/j.ccr.2012.12.001 [doi]
LID - S1535-6108(12)00514-4 [pii]
AB  - Using sequential gene expression profiling (GEP) samples, we defined a major
      functional group related to drug resistance that contains chromosomal instability
      (CIN) genes. One CIN gene in particular, NEK2, was highly correlated with drug
      resistance, rapid relapse, and poor outcome in multiple cancers. Overexpressing
      NEK2 in cancer cells resulted in enhanced CIN, cell proliferation and drug
      resistance, while targeting NEK2 by NEK2 shRNA overcame cancer cell drug
      resistance and induced apoptosis in vitro and in a xenograft myeloma mouse model.
      High expression of NEK2 induced drug resistance mainly through activation of the 
      efflux pumps. Thus, NEK2 represents a strong predictor for drug resistance and
      poor prognosis in cancer and could be an important target for cancer therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Zhou, Wen
AU  - Zhou W
AD  - Division of Hematology, Oncology, and Blood and Marrow Transplantation,
      Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
FAU - Yang, Ye
AU  - Yang Y
FAU - Xia, Jiliang
AU  - Xia J
FAU - Wang, He
AU  - Wang H
FAU - Salama, Mohamed E
AU  - Salama ME
FAU - Xiong, Wei
AU  - Xiong W
FAU - Xu, Hongwei
AU  - Xu H
FAU - Shetty, Shashirekha
AU  - Shetty S
FAU - Chen, Tiehua
AU  - Chen T
FAU - Zeng, Zhaoyang
AU  - Zeng Z
FAU - Shi, Lei
AU  - Shi L
FAU - Zangari, Maurizio
AU  - Zangari M
FAU - Miles, Rodney
AU  - Miles R
FAU - Bearss, David
AU  - Bearss D
FAU - Tricot, Guido
AU  - Tricot G
FAU - Zhan, Fenghuang
AU  - Zhan F
LA  - eng
SI  - GEO/GSE19554
GR  - R01 CA152105/CA/NCI NIH HHS/United States
GR  - R01CA115399/CA/NCI NIH HHS/United States
GR  - R01CA152105/CA/NCI NIH HHS/United States
GR  - R21 CA143887/CA/NCI NIH HHS/United States
GR  - R21CA143887/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.- (NEK2 protein, human)
RN  - EC 2.7.11.1 (Protein-Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/metabolism/*therapeutic use
MH  - Cell Proliferation
MH  - Chromosomal Instability/genetics
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Gene Expression Profiling
MH  - Humans
MH  - Male
MH  - Mice
MH  - Multiple Myeloma/diagnosis/drug therapy/*genetics
MH  - Prognosis
MH  - Protein-Serine-Threonine Kinases/antagonists & inhibitors/*genetics
MH  - RNA Interference
PMC - PMC3954609
MID - NIHMS431111
OID - NLM: NIHMS431111
OID - NLM: PMC3954609
EDAT- 2013/01/19 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/01/19 06:00
PHST- 2010/11/14 [received]
PHST- 2011/03/22 [revised]
PHST- 2012/12/04 [accepted]
AID - S1535-6108(12)00514-4 [pii]
AID - 10.1016/j.ccr.2012.12.001 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):48-62. doi: 10.1016/j.ccr.2012.12.001.

PMID- 23328479
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130118
DCOM- 20130326
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Sphingosine 1-phosphate is a missing link between chronic inflammation and colon 
      cancer.
PG  - 5-7
LID - 10.1016/j.ccr.2012.12.005 [doi]
LID - S1535-6108(12)00516-8 [pii]
AB  - In this issue of Cancer Cell, Liang and colleagues demonstrated that sphingosine 
      kinase 1, the enzyme that catalyzes formation of the biologically active lipid
      sphingosine 1-phosphate, drives a malicious amplification loop involving
      sphingosine 1-phosphate receptor 1 and the NF-kappaB/IL-6/STAT3 pathway. This
      appears critical for progression from chronic inflammation to colon cancer.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Pyne, Nigel J
AU  - Pyne NJ
AD  - Strathclyde Institute of Pharmacy and Biomedical Sciences, University of
      Strathclyde, Glasgow, UK. n.j.pyne@strath.ac.uk
FAU - Pyne, Susan
AU  - Pyne S
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Jan 14;23(1):107-20. PMID: 23273921
EDAT- 2013/01/19 06:00
MHDA- 2013/01/19 06:01
CRDT- 2013/01/19 06:00
AID - S1535-6108(12)00516-8 [pii]
AID - 10.1016/j.ccr.2012.12.005 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):5-7. doi: 10.1016/j.ccr.2012.12.005.

PMID- 23328478
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130118
DCOM- 20130326
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Smoothing out drug resistance.
PG  - 3-5
LID - 10.1016/j.ccr.2012.12.011 [doi]
LID - S1535-6108(12)00519-3 [pii]
AB  - Smoothened inhibitors have emerged as successful treatment alternatives for
      Hedgehog pathway-dependent tumors, but they are linked with the appearance of
      drug resistance. In this issue of Cancer Cell, Kim and colleagues overcome such
      resistance by combining approved drugs itraconazole and arsenic trioxide, thus
      opening a path toward new treatment options.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Kasper, Maria
AU  - Kasper M
AD  - Karolinska Institutet, Center for Biosciences and Department of Biosciences and
      Nutrition, Novum, Huddinge, Sweden.
FAU - Toftgard, Rune
AU  - Toftgard R
LA  - eng
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Jan 14;23(1):23-34. PMID: 23291299
EDAT- 2013/01/19 06:00
MHDA- 2013/01/19 06:01
CRDT- 2013/01/19 06:00
AID - S1535-6108(12)00519-3 [pii]
AID - 10.1016/j.ccr.2012.12.011 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):3-5. doi: 10.1016/j.ccr.2012.12.011.

PMID- 23328477
OWN - NLM
STAT- PubMed-not-MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20130416
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Epigenetic abnormalities in cancer find a "home on the range".
PG  - 1-3
LID - 10.1016/j.ccr.2012.12.018 [doi]
LID - S1535-6108(12)00520-X [pii]
AB  - Recent studies have highlighted large genomic regions prone to undergo epigenetic
      changes in cancers. In this issue of Cancer Cell, Bert and colleagues describe
      novel genomic domains with aberrant epigenetic changes involving concordant
      activation of neighboring genes. These domains involve aberrant CpG-island
      hypermethylation similar to that observed in gene silencing.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Easwaran, Hariharan
AU  - Easwaran H
AD  - The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical
      Institutions, Baltimore, MD 21287, USA. heaswar2@jhmi.edu
FAU - Baylin, Stephen B
AU  - Baylin SB
LA  - eng
GR  - R01 CA043318/CA/NCI NIH HHS/United States
PT  - Comment
PT  - Journal Article
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
CON - Cancer Cell. 2013 Jan 14;23(1):9-22. PMID: 23245995
PMC - PMC3586528
MID - NIHMS443282
OID - NLM: NIHMS443282
OID - NLM: PMC3586528
EDAT- 2013/01/19 06:00
MHDA- 2013/01/19 06:01
CRDT- 2013/01/19 06:00
AID - S1535-6108(12)00520-X [pii]
AID - 10.1016/j.ccr.2012.12.018 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):1-3. doi: 10.1016/j.ccr.2012.12.018.

PMID- 23291299
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20141104
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor
      growth associated with acquired resistance to smoothened antagonists.
PG  - 23-34
LID - 10.1016/j.ccr.2012.11.017 [doi]
LID - S1535-6108(12)00495-3 [pii]
AB  - Recognition of the multiple roles of Hedgehog signaling in cancer has prompted
      intensive efforts to develop targeted pathway inhibitors. Leading inhibitors in
      clinical development act by binding to a common site within Smoothened, a
      critical pathway component. Acquired Smoothened mutations, including SMO(D477G), 
      confer resistance to these inhibitors. Here, we report that itraconazole and
      arsenic trioxide, two agents in clinical use that inhibit Hedgehog signaling by
      mechanisms distinct from that of current Smoothened antagonists, retain
      inhibitory activity in vitro in the context of all reported resistance-conferring
      Smoothened mutants and GLI2 overexpression. Itraconazole and arsenic trioxide,
      alone or in combination, inhibit the growth of medulloblastoma and basal cell
      carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant 
      SMO(D477G) medulloblastoma.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Kim, James
AU  - Kim J
AD  - Institute for Stem Cell Biology and Regenerative Medicine, Stanford University,
      Stanford, CA 94305, USA.
FAU - Aftab, Blake T
AU  - Aftab BT
FAU - Tang, Jean Y
AU  - Tang JY
FAU - Kim, Daniel
AU  - Kim D
FAU - Lee, Alex H
AU  - Lee AH
FAU - Rezaee, Melika
AU  - Rezaee M
FAU - Kim, Jynho
AU  - Kim J
FAU - Chen, Baozhi
AU  - Chen B
FAU - King, Emily M
AU  - King EM
FAU - Borodovsky, Alexandra
AU  - Borodovsky A
FAU - Riggins, Gregory J
AU  - Riggins GJ
FAU - Epstein, Ervin H Jr
AU  - Epstein EH Jr
FAU - Beachy, Philip A
AU  - Beachy PA
FAU - Rudin, Charles M
AU  - Rudin CM
LA  - eng
GR  - P50 CA058184/CA/NCI NIH HHS/United States
GR  - P50-CA058184/CA/NCI NIH HHS/United States
GR  - Howard Hughes Medical Institute/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130103
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Anilides)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Arsenicals)
RN  - 0 (Hedgehog Proteins)
RN  - 0 (HhAntag691)
RN  - 0 (Oxides)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, G-Protein-Coupled)
RN  - 0 (Smo protein, mouse)
RN  - 1327-53-3 (arsenic trioxide)
RN  - 304NUG5GF4 (Itraconazole)
SB  - IM
CIN - Cancer Cell. 2013 Jan 14;23(1):3-5. PMID: 23328478
MH  - Anilides/pharmacology/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Arsenicals/pharmacology/*therapeutic use
MH  - Carcinoma, Basal Cell/*drug therapy/metabolism/pathology
MH  - Drug Resistance, Neoplasm
MH  - Hedgehog Proteins/metabolism/*physiology
MH  - Itraconazole/pharmacology/*therapeutic use
MH  - Medulloblastoma/*drug therapy/metabolism/pathology
MH  - Mice
MH  - Oxides/pharmacology/*therapeutic use
MH  - Pyridines/pharmacology/therapeutic use
MH  - Receptors, G-Protein-Coupled/antagonists & inhibitors
MH  - Signal Transduction/*drug effects
PMC - PMC3548977
MID - NIHMS426575
OID - NLM: NIHMS426575
OID - NLM: PMC3548977
EDAT- 2013/01/08 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/01/08 06:00
PHST- 2012/03/14 [received]
PHST- 2012/08/27 [revised]
PHST- 2012/11/28 [accepted]
PHST- 2013/01/03 [aheadofprint]
AID - S1535-6108(12)00495-3 [pii]
AID - 10.1016/j.ccr.2012.11.017 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013
      Jan 3.

PMID- 23273921
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20141104
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal
      inflammation, and development of colitis-associated cancer.
PG  - 107-20
LID - 10.1016/j.ccr.2012.11.013 [doi]
LID - S1535-6108(12)00492-8 [pii]
AB  - Inflammatory bowel disease is an important risk factor for colorectal cancer. We 
      show that sphingosine-1-phosphate (S1P) produced by upregulation of sphingosine
      kinase 1 (SphK1) links chronic intestinal inflammation to colitis-associated
      cancer (CAC) and both are exacerbated by deletion of Sphk2. S1P is essential for 
      production of the multifunctional NF-kappaB-regulated cytokine IL-6, persistent
      activation of the transcription factor STAT3, and consequent upregulation of the 
      S1P receptor, S1PR1. The prodrug FTY720 decreased SphK1 and S1PR1 expression and 
      eliminated the NF-kappaB/IL-6/STAT3 amplification cascade and development of CAC,
      even in Sphk2(-/-) mice, and may be useful in treating colon cancer in
      individuals with ulcerative colitis. Thus, the SphK1/S1P/S1PR1 axis is at the
      nexus between NF-kappaB and STAT3 and connects chronic inflammation and CAC.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Liang, Jie
AU  - Liang J
AD  - Department of Biochemistry and Molecular Biology and the Massey Cancer Center,
      Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
FAU - Nagahashi, Masayuki
AU  - Nagahashi M
FAU - Kim, Eugene Y
AU  - Kim EY
FAU - Harikumar, Kuzhuvelil B
AU  - Harikumar KB
FAU - Yamada, Akimitsu
AU  - Yamada A
FAU - Huang, Wei-Ching
AU  - Huang WC
FAU - Hait, Nitai C
AU  - Hait NC
FAU - Allegood, Jeremy C
AU  - Allegood JC
FAU - Price, Megan M
AU  - Price MM
FAU - Avni, Dorit
AU  - Avni D
FAU - Takabe, Kazuaki
AU  - Takabe K
FAU - Kordula, Tomasz
AU  - Kordula T
FAU - Milstien, Sheldon
AU  - Milstien S
FAU - Spiegel, Sarah
AU  - Spiegel S
LA  - eng
GR  - 5P30NS047463/NS/NINDS NIH HHS/United States
GR  - K12 HD055881/HD/NICHD NIH HHS/United States
GR  - K12HD055881/HD/NICHD NIH HHS/United States
GR  - P30CA16059/CA/NCI NIH HHS/United States
GR  - R01 CA061774/CA/NCI NIH HHS/United States
GR  - R01 CA160688/CA/NCI NIH HHS/United States
GR  - R01CA61774/CA/NCI NIH HHS/United States
GR  - R37 GM043880/GM/NIGMS NIH HHS/United States
GR  - R37GM043880/GM/NIGMS NIH HHS/United States
GR  - T32 HL094290/HL/NHLBI NIH HHS/United States
GR  - T32HL094290/HL/NHLBI NIH HHS/United States
GR  - U19 AI077435/AI/NIAID NIH HHS/United States
GR  - U19AI077435/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20121227
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Interleukin-6)
RN  - 0 (Lysophospholipids)
RN  - 0 (NF-kappa B)
RN  - 0 (Propylene Glycols)
RN  - 0 (STAT3 Transcription Factor)
RN  - 0 (Stat3 protein, mouse)
RN  - 26993-30-6 (sphingosine 1-phosphate)
RN  - 3QN8BYN5QF (fingolimod)
RN  - EC 2.7.1.- (Phosphotransferases (Alcohol Group Acceptor))
RN  - EC 2.7.1.- (sphingosine kinase)
RN  - NGZ37HRE42 (Sphingosine)
SB  - IM
CIN - Nat Rev Cancer. 2013 Mar;13(3):148. PMID: 23344496
CIN - Cancer Cell. 2013 Jan 14;23(1):5-7. PMID: 23328479
MH  - Animals
MH  - Cell Transformation, Neoplastic/genetics/pathology
MH  - Colitis/complications/drug therapy/*genetics/pathology
MH  - Colon/drug effects/metabolism/pathology
MH  - Gene Deletion
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Interleukin-6/metabolism
MH  - Lysophospholipids/genetics/metabolism/*physiology
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Phosphotransferases (Alcohol Group Acceptor)/*genetics
MH  - Propylene Glycols/pharmacology/therapeutic use
MH  - STAT3 Transcription Factor/metabolism
MH  - Sphingosine/*analogs &
      derivatives/genetics/metabolism/pharmacology/physiology/therapeutic use
MH  - Tumor Microenvironment/drug effects
PMC - PMC3578577
MID - NIHMS425539
OID - NLM: NIHMS425539
OID - NLM: PMC3578577
EDAT- 2013/01/01 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/01/01 06:00
PHST- 2012/02/06 [received]
PHST- 2012/09/18 [revised]
PHST- 2012/11/26 [accepted]
PHST- 2012/12/27 [aheadofprint]
AID - S1535-6108(12)00492-8 [pii]
AID - 10.1016/j.ccr.2012.11.013 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):107-20. doi: 10.1016/j.ccr.2012.11.013. Epub 2012 
      Dec 27.

PMID- 23273920
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20130402
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Loss of p53 in enterocytes generates an inflammatory microenvironment enabling
      invasion and lymph node metastasis of carcinogen-induced colorectal tumors.
PG  - 93-106
LID - 10.1016/j.ccr.2012.11.014 [doi]
LID - S1535-6108(12)00493-X [pii]
AB  - Loss of p53 is considered to allow progression of colorectal tumors from the
      adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell
      (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is
      insufficient to initiate intestinal tumorigenesis but markedly enhances
      carcinogen-induced tumor incidence and leads to invasive cancer and lymph node
      metastasis. Whereas p53 controls DNA damage and IEC survival during the
      initiation stage, loss of p53 during tumor progression is associated with
      increased intestinal permeability, causing formation of an NF-kappaB-dependent
      inflammatory microenvironment and the induction of epithelial-mesenchymal
      transition. Thus, we propose a p53-controlled tumor-suppressive function that is 
      independent of its well-established role in cell-cycle regulation, apoptosis, and
      senescence.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Schwitalla, Sarah
AU  - Schwitalla S
AD  - Institute of Molecular Immunology, Klinikum rechts der Isar, Technical University
      Munich, Munich, Germany.
FAU - Ziegler, Paul K
AU  - Ziegler PK
FAU - Horst, David
AU  - Horst D
FAU - Becker, Valentin
AU  - Becker V
FAU - Kerle, Irina
AU  - Kerle I
FAU - Begus-Nahrmann, Yvonne
AU  - Begus-Nahrmann Y
FAU - Lechel, Andre
AU  - Lechel A
FAU - Rudolph, K Lenhard
AU  - Rudolph KL
FAU - Langer, Rupert
AU  - Langer R
FAU - Slotta-Huspenina, Julia
AU  - Slotta-Huspenina J
FAU - Bader, Franz G
AU  - Bader FG
FAU - Prazeres da Costa, Olivia
AU  - Prazeres da Costa O
FAU - Neurath, Markus F
AU  - Neurath MF
FAU - Meining, Alexander
AU  - Meining A
FAU - Kirchner, Thomas
AU  - Kirchner T
FAU - Greten, Florian R
AU  - Greten FR
LA  - eng
SI  - GEO/GSE27868
SI  - GEO/GSE28129
GR  - 281967/European Research Council/International
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121227
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Carcinogens)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
CIN - Nat Rev Cancer. 2013 Mar;13(3):148. PMID: 23344496
MH  - Adenoma/chemically induced/genetics/pathology
MH  - Animals
MH  - Carcinogens/*toxicity
MH  - Carcinoma/chemically induced/genetics/pathology
MH  - Colorectal Neoplasms/chemically induced/genetics/*pathology
MH  - Disease Models, Animal
MH  - Lymph Nodes/*pathology
MH  - Mice
MH  - Mutagenesis, Site-Directed
MH  - Neoplasm Invasiveness/genetics
MH  - Neoplasm Metastasis
MH  - *Tumor Microenvironment
MH  - Tumor Suppressor Protein p53/*genetics
EDAT- 2013/01/01 06:00
MHDA- 2013/03/27 06:00
CRDT- 2013/01/01 06:00
PHST- 2011/03/09 [received]
PHST- 2012/09/17 [revised]
PHST- 2012/11/26 [accepted]
PHST- 2012/12/27 [aheadofprint]
AID - S1535-6108(12)00493-X [pii]
AID - 10.1016/j.ccr.2012.11.014 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):93-106. doi: 10.1016/j.ccr.2012.11.014. Epub 2012 
      Dec 27.

PMID- 23260764
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20140513
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - The androgen receptor induces a distinct transcriptional program in
      castration-resistant prostate cancer in man.
PG  - 35-47
LID - 10.1016/j.ccr.2012.11.010 [doi]
LID - S1535-6108(12)00489-8 [pii]
AB  - The androgen receptor (AR) regulates prostate cell growth in man, and prostate
      cancer is the commonest cancer in men in the UK. We present a comprehensive
      analysis of AR binding sites in human prostate cancer tissues, including
      castrate-resistant prostate cancer (CRPC). We identified thousands of AR binding 
      sites in CRPC tissue, most of which were not identified in PC cell lines. Many
      adjacent genes showed AR regulation in xenografts but not in cultured LNCaPs,
      demonstrating an in-vivo-restricted set of AR-regulated genes. Functional studies
      support a model of altered signaling in vivo that directs AR binding. We
      identified a 16 gene signature that outperformed a larger in-vitro-derived
      signature in clinical data sets, showing the importance of persistent AR
      signaling in CRPC.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Sharma, Naomi L
AU  - Sharma NL
AD  - Uro-oncology Research Group, Cambridge Research Institute, Cambridge, UK.
FAU - Massie, Charlie E
AU  - Massie CE
FAU - Ramos-Montoya, Antonio
AU  - Ramos-Montoya A
FAU - Zecchini, Vincent
AU  - Zecchini V
FAU - Scott, Helen E
AU  - Scott HE
FAU - Lamb, Alastair D
AU  - Lamb AD
FAU - MacArthur, Stewart
AU  - MacArthur S
FAU - Stark, Rory
AU  - Stark R
FAU - Warren, Anne Y
AU  - Warren AY
FAU - Mills, Ian G
AU  - Mills IG
FAU - Neal, David E
AU  - Neal DE
LA  - eng
SI  - GEO/GSE28219
SI  - GEO/GSE28680
GR  - 079249/Wellcome Trust/United Kingdom
GR  - G0900871/Medical Research Council/United Kingdom
GR  - Cancer Research UK/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121220
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AR protein, human)
RN  - 0 (Histones)
RN  - 0 (Receptors, Androgen)
SB  - IM
CIN - Cancer Biol Ther. 2014 Jan;15(1):16-8. PMID: 24253417
MH  - Animals
MH  - Binding Sites
MH  - Cell Line, Tumor
MH  - *Gene Expression Regulation, Neoplastic
MH  - Histones/metabolism
MH  - Humans
MH  - Male
MH  - Mice
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - Receptors, Androgen/metabolism/*physiology
EDAT- 2012/12/25 06:00
MHDA- 2013/03/27 06:00
CRDT- 2012/12/25 06:00
PHST- 2011/08/11 [received]
PHST- 2012/03/30 [revised]
PHST- 2012/11/19 [accepted]
PHST- 2012/12/20 [aheadofprint]
AID - S1535-6108(12)00489-8 [pii]
AID - 10.1016/j.ccr.2012.11.010 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):35-47. doi: 10.1016/j.ccr.2012.11.010. Epub 2012
      Dec 20.

PMID- 23245996
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
LR  - 20150206
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor
      regressions in KRAS mutant cancer models.
PG  - 121-8
LID - 10.1016/j.ccr.2012.11.007 [doi]
LID - S1535-6108(12)00487-4 [pii]
AB  - KRAS is the most commonly mutated oncogene, yet no effective targeted therapies
      exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy
      to identify genes that, when inhibited, cooperate with MEK inhibitors to
      effectively treat KRAS mutant cancer cells. The anti-apoptotic BH3 family gene
      BCL-XL emerged as a top hit through this approach. ABT-263 (navitoclax), a
      chemical inhibitor that blocks the ability of BCL-XL to bind and inhibit
      pro-apoptotic proteins, in combination with a MEK inhibitor led to dramatic
      apoptosis in many KRAS mutant cell lines from different tissue types. This
      combination caused marked in vivo tumor regressions in KRAS mutant xenografts and
      in a genetically engineered KRAS-driven lung cancer mouse model, supporting
      combined BCL-XL/MEK inhibition as a potential therapeutic approach for KRAS
      mutant cancers.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Corcoran, Ryan B
AU  - Corcoran RB
AD  - Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.
FAU - Cheng, Katherine A
AU  - Cheng KA
FAU - Hata, Aaron N
AU  - Hata AN
FAU - Faber, Anthony C
AU  - Faber AC
FAU - Ebi, Hiromichi
AU  - Ebi H
FAU - Coffee, Erin M
AU  - Coffee EM
FAU - Greninger, Patricia
AU  - Greninger P
FAU - Brown, Ronald D
AU  - Brown RD
FAU - Godfrey, Jason T
AU  - Godfrey JT
FAU - Cohoon, Travis J
AU  - Cohoon TJ
FAU - Song, Youngchul
AU  - Song Y
FAU - Lifshits, Eugene
AU  - Lifshits E
FAU - Hung, Kenneth E
AU  - Hung KE
FAU - Shioda, Toshi
AU  - Shioda T
FAU - Dias-Santagata, Dora
AU  - Dias-Santagata D
FAU - Singh, Anurag
AU  - Singh A
FAU - Settleman, Jeffrey
AU  - Settleman J
FAU - Benes, Cyril H
AU  - Benes CH
FAU - Mino-Kenudson, Mari
AU  - Mino-Kenudson M
FAU - Wong, Kwok-Kin
AU  - Wong KK
FAU - Engelman, Jeffrey A
AU  - Engelman JA
LA  - eng
GR  - 1U01CA141457-01/CA/NCI NIH HHS/United States
GR  - 1U54HG006097-01/HG/NHGRI NIH HHS/United States
GR  - K08 CA120060/CA/NCI NIH HHS/United States
GR  - K08 CA166510/CA/NCI NIH HHS/United States
GR  - K08CA120060/CA/NCI NIH HHS/United States
GR  - P50 CA090578/CA/NCI NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
GR  - P50 CA127003/CA/NCI NIH HHS/United States
GR  - P50CA090578/CA/NCI NIH HHS/United States
GR  - R01 CA122794/CA/NCI NIH HHS/United States
GR  - R01 CA137008/CA/NCI NIH HHS/United States
GR  - R01 CA140594/CA/NCI NIH HHS/United States
GR  - R01 CA163896/CA/NCI NIH HHS/United States
GR  - R01CA122794/CA/NCI NIH HHS/United States
GR  - R01CA137008/CA/NCI NIH HHS/United States
GR  - R01CA140594/CA/NCI NIH HHS/United States
GR  - R01CA163896/CA/NCI NIH HHS/United States
GR  - T32 DK007191/DK/NIDDK NIH HHS/United States
GR  - U01 CA141457/CA/NCI NIH HHS/United States
GR  - U54 HG006097/HG/NHGRI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20121213
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (AZD 6244)
RN  - 0 (Aniline Compounds)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzimidazoles)
RN  - 0 (Sulfonamides)
RN  - 0 (bcl-X Protein)
RN  - EC 2.7.11.25 (MAP Kinase Kinase Kinases)
RN  - EC 3.6.5.2 (Kras2 protein, mouse)
RN  - EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
RN  - XKJ5VVK2WD (navitoclax)
SB  - IM
CIN - Nat Rev Drug Discov. 2013 Mar;12(3):188-9. PMID: 23449300
CIN - Nat Rev Cancer. 2013 Feb;13(2):79. PMID: 23344537
CIN - Nat Rev Clin Oncol. 2013 Feb;10(2):67. PMID: 23319137
MH  - Aniline Compounds/*pharmacology/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Benzimidazoles/*pharmacology/therapeutic use
MH  - Drug Screening Assays, Antitumor
MH  - Humans
MH  - MAP Kinase Kinase Kinases/*antagonists & inhibitors
MH  - Mice
MH  - Neoplasms/*drug therapy/genetics
MH  - Proto-Oncogene Proteins p21(ras)/*genetics/metabolism
MH  - Sulfonamides/*pharmacology/therapeutic use
MH  - bcl-X Protein/*antagonists & inhibitors
PMC - PMC3667614
MID - NIHMS428804
OID - NLM: NIHMS428804
OID - NLM: PMC3667614
EDAT- 2012/12/19 06:00
MHDA- 2013/03/27 06:00
CRDT- 2012/12/19 06:00
PHST- 2012/06/03 [received]
PHST- 2012/09/24 [revised]
PHST- 2012/11/15 [accepted]
PHST- 2012/12/13 [aheadofprint]
AID - S1535-6108(12)00487-4 [pii]
AID - 10.1016/j.ccr.2012.11.007 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):121-8. doi: 10.1016/j.ccr.2012.11.007. Epub 2012
      Dec 13.

PMID- 23245995
OWN - NLM
STAT- MEDLINE
DA  - 20130118
DCOM- 20130326
IS  - 1878-3686 (Electronic)
IS  - 1535-6108 (Linking)
VI  - 23
IP  - 1
DP  - 2013 Jan 14
TI  - Regional activation of the cancer genome by long-range epigenetic remodeling.
PG  - 9-22
LID - 10.1016/j.ccr.2012.11.006 [doi]
LID - S1535-6108(12)00486-2 [pii]
AB  - Epigenetic gene deregulation in cancer commonly occurs through chromatin
      repression and promoter hypermethylation of tumor-associated genes. However, the 
      mechanism underpinning epigenetic-based gene activation in carcinogenesis is
      still poorly understood. Here, we identify a mechanism of domain gene
      deregulation through coordinated long-range epigenetic activation (LREA) of
      regions that typically span 1 Mb and harbor key oncogenes, microRNAs, and cancer 
      biomarker genes. Gene promoters within LREA domains are characterized by a gain
      of active chromatin marks and a loss of repressive marks. Notably, although
      promoter hypomethylation is uncommon, we show that extensive DNA hypermethylation
      of CpG islands or "CpG-island borders" is strongly related to cancer-specific
      gene activation or differential promoter usage. These findings have wide
      ramifications for cancer diagnosis, progression, and epigenetic-based gene
      therapies.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Bert, Saul A
AU  - Bert SA
AD  - Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, New 
      South Wales 2010, Australia.
FAU - Robinson, Mark D
AU  - Robinson MD
FAU - Strbenac, Dario
AU  - Strbenac D
FAU - Statham, Aaron L
AU  - Statham AL
FAU - Song, Jenny Z
AU  - Song JZ
FAU - Hulf, Toby
AU  - Hulf T
FAU - Sutherland, Robert L
AU  - Sutherland RL
FAU - Coolen, Marcel W
AU  - Coolen MW
FAU - Stirzaker, Clare
AU  - Stirzaker C
FAU - Clark, Susan J
AU  - Clark SJ
LA  - eng
SI  - GEO/GSE24546
SI  - GEO/GSE38685
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121213
PL  - United States
TA  - Cancer Cell
JT  - Cancer cell
JID - 101130617
RN  - 0 (Histones)
RN  - 0 (MicroRNAs)
SB  - IM
CIN - Cancer Cell. 2013 Jan 14;23(1):1-3. PMID: 23328477
CIN - Nat Rev Cancer. 2013 Feb;13(2):76. PMID: 23329064
MH  - Cell Line, Tumor
MH  - CpG Islands
MH  - DNA Methylation
MH  - *Epigenesis, Genetic
MH  - *Gene Expression Regulation, Neoplastic
MH  - *Genome
MH  - Histones/metabolism
MH  - Humans
MH  - Male
MH  - MicroRNAs/genetics/physiology
MH  - Promoter Regions, Genetic
MH  - Prostatic Neoplasms/*genetics
EDAT- 2012/12/19 06:00
MHDA- 2013/03/27 06:00
CRDT- 2012/12/19 06:00
PHST- 2012/01/08 [received]
PHST- 2012/05/24 [revised]
PHST- 2012/11/15 [accepted]
PHST- 2012/12/13 [aheadofprint]
AID - S1535-6108(12)00486-2 [pii]
AID - 10.1016/j.ccr.2012.11.006 [doi]
PST - ppublish
SO  - Cancer Cell. 2013 Jan 14;23(1):9-22. doi: 10.1016/j.ccr.2012.11.006. Epub 2012
      Dec 13.